WO2014184639A1 - Composition comprising lactic acid bacteria for use in the preventive and/or curative treatment of recurrent cystitis - Google Patents

Composition comprising lactic acid bacteria for use in the preventive and/or curative treatment of recurrent cystitis Download PDF

Info

Publication number
WO2014184639A1
WO2014184639A1 PCT/IB2014/000731 IB2014000731W WO2014184639A1 WO 2014184639 A1 WO2014184639 A1 WO 2014184639A1 IB 2014000731 W IB2014000731 W IB 2014000731W WO 2014184639 A1 WO2014184639 A1 WO 2014184639A1
Authority
WO
WIPO (PCT)
Prior art keywords
composition
dsm
strain
bacteria
lactobacillus
Prior art date
Application number
PCT/IB2014/000731
Other languages
French (fr)
Other versions
WO2014184639A9 (en
Inventor
Giovanni Mogna
Original Assignee
Probiotical S.P.A.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to PL14732360T priority Critical patent/PL2996700T3/en
Priority to EP14732360.4A priority patent/EP2996700B1/en
Priority to ES14732360T priority patent/ES2831900T3/en
Priority to JP2016513453A priority patent/JP6600623B2/en
Priority to CN201480027970.9A priority patent/CN105377277A/en
Priority to DK14732360.4T priority patent/DK2996700T3/en
Priority to RU2015148750A priority patent/RU2015148750A/en
Priority to BR112015027536A priority patent/BR112015027536A8/en
Application filed by Probiotical S.P.A. filed Critical Probiotical S.P.A.
Priority to CA2912013A priority patent/CA2912013A1/en
Priority to US14/891,306 priority patent/US11110136B2/en
Priority to KR1020157035288A priority patent/KR102261724B1/en
Publication of WO2014184639A1 publication Critical patent/WO2014184639A1/en
Publication of WO2014184639A9 publication Critical patent/WO2014184639A9/en
Priority to US17/230,665 priority patent/US20210308197A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A61K35/741—Probiotics
    • A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
    • A61K35/747—Lactobacilli, e.g. L. acidophilus or L. brevis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A61K35/741—Probiotics
    • A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/45—Ericaceae or Vacciniaceae (Heath or Blueberry family), e.g. blueberry, cranberry or bilberry
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N1/00—Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
    • C12N1/20—Bacteria; Culture media therefor
    • C12N1/205—Bacterial isolates
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12R—INDEXING SCHEME ASSOCIATED WITH SUBCLASSES C12C - C12Q, RELATING TO MICROORGANISMS
    • C12R2001/00—Microorganisms ; Processes using microorganisms
    • C12R2001/01—Bacteria or Actinomycetales ; using bacteria or Actinomycetales
    • C12R2001/225—Lactobacillus
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12R—INDEXING SCHEME ASSOCIATED WITH SUBCLASSES C12C - C12Q, RELATING TO MICROORGANISMS
    • C12R2001/00—Microorganisms ; Processes using microorganisms
    • C12R2001/01—Bacteria or Actinomycetales ; using bacteria or Actinomycetales
    • C12R2001/225—Lactobacillus
    • C12R2001/23—Lactobacillus acidophilus
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12R—INDEXING SCHEME ASSOCIATED WITH SUBCLASSES C12C - C12Q, RELATING TO MICROORGANISMS
    • C12R2001/00—Microorganisms ; Processes using microorganisms
    • C12R2001/01—Bacteria or Actinomycetales ; using bacteria or Actinomycetales
    • C12R2001/225—Lactobacillus
    • C12R2001/25—Lactobacillus plantarum
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Definitions

  • the present invention relates to a composition comprising lactic bacteria for use in the preventive and/or curative treatment of bacterial infections and related inflammations of the urinary tract and/or bladder, in particular for the treatment of recurrent cystitis.
  • Pathogenic bacteria belonging to the species Escherichia coii are known to be able to adhere to the epithelial cell surface of the urinary bladder (urothelium). For this and other reasons, it is known that pathogenic bacteria belonging to the species Escherichia coii are responsible for more than 80% of the cases of bacterial infections, which cause bladder inflammations (cystitis). Cystitis, in particular recurrent cystitis, causes discomfort and pain, at times even in acute form.
  • the Applicant following to an extended and intense research activity, gave a response to the above-cited needs.
  • the Applicant after testing and studying many strains of lactic bacteria, succeeded to select only some of them.
  • the selected strains have, at the same time, an activity against the pathogenic bacteria E.coli which cause infections and a high anti-inflammatory activity since they are strains of bacteria producing interleukin 4 (IL-4) and interleukin 10 (IL-10).
  • IL-4 interleukin 4
  • IL-10 interleukin 10
  • compositions for use in the preventive and/or curative treatment of bacterial infections and related inflammations of the urinary tract and/or bladder having the characteristics as disclosed in the appended claim.
  • Said composition is preferably for use in the preventive and/or curative treatment of cystitis, in particular recurrent cystitis.
  • preventive and/or curative treatment is meant to also include circumstances wherein the urinary tract and/or bladder inflammation is limited, reduced or attenuated, which improve the health conditions of the subject being treated.
  • composition in the context of the present invention by composition is meant to include a pharmaceutical composition, or a supplement product or a medical device or a food composition.
  • composition comprising a mixture of bacteria which comprises or, alternatively, consists of: strains of bacteria having both a specific antibacterial activity against E.coli and an antiinflammatory activity with stimulation of the Interleukin IL-4 and Interleukin IL-10 production, and strains of bacteria having an oxalate-degrading activity.
  • composition wherein said mixture comprises or, alternatively, consists of: at least a strain of bacteria having both a specific antibacterial activity against E.coli and an anti-inflammatory activity with stimulation of the Interleukin IL-4 and Interleukin IL-10 production, combined with at least a strain of bacteria having an oxalate-degrading activity.
  • composition comprising or, alternatively, consisting of a mixture of bacteria which comprises or, alternatively, consists of at least a strain of bacteria selected from the group comprising the strain Lactobacillus plantarum LMG P-21021 -LP01 and the strain Lactobacillus plantarum LMG P-21020 -LP02, combined with at least a strain of bacteria selected from the group comprising the strain Lactobacillus paracasei DS 24243 -LPC09, the strain Lactobacillus gasseri DSM 18299 -LGS01 , the strain Lactobacillus gasseri DSM 18300 -LGS02, the strain Lactobacillus acidophilus DSM 24303 -LA07 and the strain Lactobacillus acidophilus DSM 21717 -LA02, for use in the preventive and/or curative treatment of bacterial infections and related inflammations of the urinary tract and/or bladder.
  • the strain Lactobacillus plantarum LMG P-21021 -LP01 was deposited by Mofin Sri Company on 16.10.2001 at the BCCM LMG center.
  • the strain Lactobacillus plantarum LMG P-21020 -LP02 was deposited by Mofin Sri Company on 16.10.2001 at the BCCM LMG center.
  • strain Lactobacillus paracasei DSM 24243 -LPC09 was deposited by Probiotical S.p.A. Company on 23.11.2010 at the DSMZ center.
  • strain Lactobacillus gasseri DSM 18299 -LGS01 was deposited by Anidral Sri Company, now Probiotical S.p.A., on 24.05.2006 at the DSMZ center.
  • strain Lactobacillus gasseri DSM 18300 -LGS02 was deposited by Anidral Sri Company, now Probiotical S.p.A., on 24.05.2006 at the DSMZ center.
  • strain Lactobacillus acidophilus DSM 24303 -LA07 was deposited by Probiotical S.p.A. Company on 23,11.2010 at the DSMZ center.
  • strain Lactobacillus acidophilus DSM 21717 -LA02 was deposited by Probiotical S.p.A. Company on 06.08.2008 at the DSMZ center.
  • the composition comprises or, alternatively, consists of a mixture of bacteria which comprises or, alternatively, consists of Lactobacillus plantarum LMG P-21021 -LP01 combined with at least a strain of bacteria selected from the group comprising the strain Lactobacillus paracasei DSM 24243 -LPC09, the strain Lactobacillus gasseri DSM 18299 -LGS01 , the strain Lactobacillus gasseri DSM 18300 -LGS02, the strain Lactobacillus acidophilus DSM 24303 -LA07 and the strain Lactobacillus acidophilus DSM 21717 -LA02; preferably in a weight ratio comprised from 4:1 to 3:1; even more preferably 1 :1.
  • Said compositions are for use in the preventive and/or curative treatment of cystitis, in particular of recurrent cystitis.
  • the composition comprises or, alternatively, consists of a mixture of bacteria which comprises or, alternatively, consists of Lactobacillus plantarum LMG P-21020 -LP02 combined with at least a strain of bacteria selected from the group comprising the strain Lactobacillus paracasei DSM 24243 -LPC09, the strain Lactobacillus gasseri DSM 18299 -LGS01 , the strain Lactobacillus gasseri DSM 18300 -LGS02, the strain Lactobacillus acidophilus DSM 24303 -LA07 and the strain Lactobacillus acidophilus DSM 21717 -LA02; preferably in a weight ratio comprised from 4:1 to 3:1 ; even more preferably 1 :1.
  • compositions are for use in the preventive and/or curative treatment of cystitis, in particular of recurrent cystitis.
  • Said compositions can further comprise a cranberry extract, preferably a dry cranberry extract, and/or can further comprise a D-mannose.
  • said compositions can comprise, in addition to the strains of bacteria described above and the amounts disclosed above, a cranberry extract, preferably a dry cranberry extract; and/or can comprise a D-mannose; and/or can comprise a plant gum and/or a plant gelatin.
  • the plant gum and/or the plant gelatin is preferably selected from the group comprising a tannate or a gelatin tannate, an alginate, a xyloglucan or xylogel, a guar gum, a tara gum, an acacia, carob, oat, bamboo fiber, citrus fruit fibers and glucomannans.
  • it is a guar gum.
  • the selected plant gum and/or plant gelatin reduces the bacterial translocation of E.coli from the intestine to the bladder.
  • compositions can further comprise a fiber with prebiotic activity selected from inulin, fructo-oligosaccharides (FOS), galacto- and trans-galacto-oligosaccharides (GOS and TOS), gluco- oligosaccharides (GOSa), xylo-oligosaccharides, (XOS), chitosan-oligosaccharides (COS), soy-oligosaccharides (SOS), isomalto-oligosaccharides (IMOS), resistant starch, pectins, psyllium, arabino-galactans, gluco-mannans and galacto-mannans.
  • a fiber with prebiotic activity selected from inulin, fructo-oligosaccharides (FOS), galacto- and trans-galacto-oligosaccharides (GOS and TOS), gluco- oligosaccharides (GOSa), xylo-oligosaccharides, (XOS),
  • composition of the present invention comprises or, alternatively, consists of:
  • a mixture of bacteria which comprises or, alternatively, consists of Lactobacillus plantarum LMG P-21021 - LP01 and Lactobacillus paracasei DSM 24243 -LPC09; preferably in a weight ratio comprised from 4:1 to 3:1 ; even more preferably 1 :1 ,
  • a cranberry extract preferably a dry cranberry extract, a D-mannose and
  • a guar gum preferably in a weight ratio 1 :1 :1 , and
  • a fructo-oligosaccharide -FOS preferably in a weight ratio 5:1 relative to the weight of cranberry extract.
  • composition of the present invention comprises or, alternatively, consists of:
  • a mixture of bacteria which comprises or, alternatively, consists of Lactobacillus plantarum LMG P-21020 - LP02 and Lactobacillus acidophilus DSM 21717 -LA02; preferably in a weight ratio comprised from 4:1 to 3:1 ; even more preferably 1 :1 ,
  • a cranberry extract preferably a dry cranberry extract, a D-mannose and
  • a guar gum preferably in a weight ratio 1 :1 :1 , and
  • a fructo-oligosaccharide -FOS preferably in a weight ratio 5:1 relative to the weight of cranberry extract.
  • composition of the present invention due to the presence of a cranberry extract, preferably a dry extract (trade name PACran®, a dry extract of US cranberry (Cranberry -Vaccinium macrocarpon- extract)) is able to establishing a physical-mechanical hindrance against the Escherichia coli adhesion to the epithelial cell surface of the urinary bladder (urothelium).
  • a dry extract trade name PACran®, a dry extract of US cranberry (Cranberry -Vaccinium macrocarpon- extract)
  • the activity of said cranberry extract is mediated, in particular, by the proanthocyanidin subtraction with the trimers and tetramers characterized by A-type bonds which compete with the adhesins located on the P-type fimbriae (FimH, mannose-sensitive) which uses £. coli for mediating its anchoring to the epithelial cells through specific receptors, thereby hindering in a physical-mechanical manner its adhesion and subsequent bladder colonization.
  • the strain of bacteria Lactobacillus plantarum LMG P-21021 - LP01 and/or the strain of bacteria Lactobacillus plantarum LMG P-21020 -LP02, in the presence of the cranberry extract, are able to complement and enhance the physical-mechanical hindrance exerted by the cranberry extract as described above, through a barrier-type action even at intestinal level against £ coli.
  • These two strains of bacteria Lactobacillus plantarum LMG P-21021 - LP01 and Lactobacillus plantarum LMG P-21020 -LP02 have a proven E.coli activity and a high anti-inflammatory activity since they produce interleukin 4 (IL-4) and interleukin 10 (IL-10).
  • IL-4 interleukin 4
  • IL-10 interleukin 10
  • the strain of bacteria Lactobacillus plantarum LMG P-21021 - LP01 and/or the strain of bacteria Lactobacillus plantarum LMG P-21020 -LP02 are in an amount comprised from 1 to 3 billions of viable cells/dose, even more preferably from 2 to 2.5 billions of viable cells/dose.
  • the strains of bacteria of the present invention exert a marked barrier-type action against potential Gram- negative pathogens, with particular reference to the species Escherichia coli and a high anti-inflammatory activity since they produce interleukin 4 (IL-4) and interleukin 10 (IL-10).
  • IL-4 interleukin 4
  • IL-10 interleukin 10
  • the strains of bacteria Lactobacillus paracasei DSM 24243 -LPC09, Lactobacillus gasseri DSM 18299 -LGS01 , Lactobacillus gasseri DSM 18300 -LGS02, Lactobacillus acidophilus DSM 24303 -LA07 and Lactobacillus acidophilus DSM 21717 -LA02 are able to carry out a protective action since they exert a barrier effect to the oxalates contained in the cranberry extract, preferably in the form of dry extract.
  • the metabolization of these oxalate molecules prevents the intestinal accumulation and the systemic absorption thereof, thus avoiding the establishment and the maintenance of an inflammatory condition of the intestine, particularly disadvantageous in the occurrence of diverticula.
  • strains of bacteria Lactobacillus paracasei DSM 24243 -LPC09, Lactobacillus gasseri DSM 18299 -LGS01, Lactobacillus gasseri DSM 18300 -LGS02, Lactobacillus acidophilus DSM 24303 -LA07 and Lactobacillus acidophilus DSM 21717 -LA02 metabolize the oxalates and, therefore, have a proved anti-renal gravel activity.
  • These strains of bacteria prevent the renal accumulation of oxalates thus avoiding the renal gravel formation and, thereby, impeding the establishment and the maintenance of an inflammatory condition of the urinary tract particularly disadvantageous for the health status of a bladder subjected to recurrent cystitis.
  • the presence of strains of bacteria degrading oxalates in the composition of the present invention is also important for the following reason.
  • the cranberry extract contains a fair oxalate amount. A prolonged use of cranberry extract could lead to renal gravel formation, which may force the subject to suspend the use thereof.
  • the use of strains degrading oxalates of the present invention prevents this drawback allowing a prolonged administration of cranberry extract.
  • the strains of bacteria Lactobacillus paracasei DSM 24243 -LPC09, Lactobacillus gasseri DSM 18299 -LGS01 , Lactobacillus gasseri DSM 18300 -LGS02, Lactobacillus acidophilus DSM 24303 -LA07 and Lactobacillus acidophilus DSM 21717 -LA02 are in an amount comprised from 0.5 to 2 billions of viable cells/dose, even more preferably from 1 to 1.5 billions of viable cells/dose.
  • the composition further comprises D-mannose, which enhances the barrier effect exerted by the cranberry extract.
  • D-mannose in a simple sugar, namely a monosaccharide which, once absorbed in the blood circulation, is neither transformed in glycogen nor exploited by the organism, with a subsequent removal by the kidney and achievement of high concentrations in the urinary tract wherein it will exert its hindering effects against the bacteria being present.
  • D-mannose has a high affinity for mannose-sensitive lectins, typical proteins of cell membranes of the human organism used by many bacteria for adhering to the urinary mucosae.
  • D-mannose also exerts a mechanical action, which inhibits the formation of biofilms that many bacteria are able to produce with the dual purpose of protecting from our immune system elements and from antibiotics, as well as more effectively adhering to the mucosal surface.
  • the composition of the present invention can further comprise at least a gum, among those described above, which decreases the bacterial translocation of E.coli from the intestine to the bladder.
  • the gum can be a plant gum and/or a plant gelatin.
  • the plant gum and/or the plant gelatin is preferably selected from the group comprising a tannate or a gelatin tannate, an alginate, a xyloglucan or xylogel, a guar gum, a tara gum, an acacia, carob, oat, bamboo fiber, citrus fruit fibers and glucomannans.
  • it is a guar gum.
  • the selected plant gum and/or plant gelatin reduces the bacterial translocation of E.coli from the intestine to the bladder.
  • it is a guar gum.
  • the guar gum exerts a mechanical action at intestinal level, hindering the adhesion of Escherichia coli and other pathogens to the mucosa of the organ, thus reducing their translocation through the intestinal wall and the subsequent risk of infection of adjacent organs.
  • the gum acts by forming a hydrophilic gel, which evenly distributes over the mucosal surface, restoring the physiological barrier effect of this organ, which typically results impaired in the event of intestinal infections by Escherichia coli or other pathogens.
  • composition of the present invention further comprises a fiber with prebiotic activity (prebiotic fiber), which can be selected from inulin, fructo-oligosaccharides (FOS), galacto- and trans-galacto- oligosaccharides (GOS and TOS), gluco-oligosaccharides (GOSa), xylo-oligosaccharides, (XOS), chitosan- oligosaccharides (COS), soy-oligosaccharides (SOS), isomalto-oligosaccharides (IMOS), resistant starch, pectins, psyllium, arabino-galactans, gluco-mannans and galacto-mannans.
  • prebiotic fiber can be selected from inulin, fructo-oligosaccharides (FOS), galacto- and trans-galacto- oligosaccharides (GOS and TOS), gluco-oligosaccharides (GOSa), xylo-oligo
  • composition of the present invention can further comprise excipients selected from natural flavors, anti- caking agents such as silicon dioxide, black carrot anthocyanins, sucralose.
  • excipients selected from natural flavors, anti- caking agents such as silicon dioxide, black carrot anthocyanins, sucralose.
  • the mixture of bacteria has a bacterial load comprised from 1x10 8 to 1x10 12 CFU/g of mixture.
  • the composition of the present invention which contains said mixture of bacteria has a bacterial load of about 5x10 7 -5x10 9 CFU/composition.
  • composition comprising a mixture, which comprises or, alternatively, consists of:
  • composition further comprises:
  • a specific muco-adhesive gelling complex comprised of EPS, exopolysaccharides of bacterial origin (produced by Streptococcus thermophilus ST10 DSM 25246 and tara gum, a polysaccharide of plant origin.
  • Said gelling complex is able to establish a mechanical barrier effect throughout the gastro-intestinal tract.
  • Said composition further contains (d) a specific dry extract of US cranberry (Cranberry - PACran®) and (e) a suitable amount of D-mannose (composition).
  • composition Due to the presence of cranberry and D-mannose the composition is able to establishing a hindering action of physical-mechanical type against the adhesion of Escherichia coli to the epithelial cell surface of the urinary bladder, responsible for most of the cases of bacterial infections which cause inflammations of this organ (cystitis).
  • the composition is able to establish a natural physical-mechanical hindrance against the adhesion of Escherichia coli to the epithelial cell surface of bladder and urinary tract. Its main activity is related to the proanthocyanidin subfraction (phytochemical component of fruits) containing trace elements which compete with the adhesins located on the P-type fimbriae (Fim H, mannose-sensitive) which uses E. coli for mediating its anchoring to the epithelial cells, thereby hindering in a physical-mechanical manner its adhesion and subsequent colonization of urinary tract and bladder,
  • D-mannose a simple sugar.
  • UPEC bacteria by binding the D-mannose molecules through the P-type fimbriae, remain in free form in the urine and, thus, are more easily removed by urination.
  • D-mannose exerts a mechanical action inhibiting the formation of biofilms that many bacteria are able to produce.
  • D-mannose is able to bind the cells of the bladder mucosa (of which is constitutive part) restoring a protective layer similar to the physiological one comprised of glycosaminoglycans, which is usually damaged by recurrent inflammations.
  • the composition further comprises a suitable amount of tara gum which, due to its gelling and muco-adhesive properties, is capable to form a hydrogel within few minutes after ingestion, by virtue of its thixotropic characteristics, thereby creating, in the first part of the gastrointestinal tract a mechanical barrier action against the adhesion of Escherichia coli and other pathogens to the mucosa of the organ, thus reducing the translocation thereof through the intestinal wall and the subsequent risk of infection of adjacent organs, among which mainly the bladder.
  • EPS exopolysaccharides
  • the above-cited muco-adhesive gelling complex has an innovative property which has to be taken into account: tara gum, like ail the gums of plant origin, is progressively degraded by the resident microbiota during its intestinal transit, thereby progressively reducing its gelling power of mechanical hindrance.
  • the gradual reduction of the plant gum action is effectively counterbalanced by the gradual increase of exopolysaccharide (EPS) release in the intestinal lumen by the bacterial strain ST10, which exerts its property mainly in ileum and colon.
  • EPS exopolysaccharide
  • the synergistic combination of tara gum and exopolysaccharides (EPS) thereby ensures the presence of gelling molecules throughout the gastro-intestinal tract, maximizing and optimizing the mechanical barrier action of the product.
  • the presence, production and retention of the hydrophilic gel in the lumen of the organ can, therefore, be considered for the first time really complete, with a first area wherein the plant gum action is maximum and a second area wherein the exopoiysaccharide (EPS) action is maximum.
  • EPS exopoiysaccharide
  • Lactobacillus plantarum LP01 (LMG P-21021) (for example 2.5 billions/daily dose) and Lactobacillus paracasei LPC09 (DSM 24343) (for example 1 billion/daily dose), mediate an enhancement of the barrier effect established by the muco-adhesive gelling complex comprised of tara gum and exopolysaccharides (EPS), by a barrier-type action against £ coli even at intestinal level.
  • EPS exopolysaccharides
  • the Applicant carried out a selection of microorganisms with a marked barrier-type action against potential Gram-negative pathogens, with particular reference to the species Escherichia coli, the main role of which in cystitis has been well demonstrated.
  • the barrier action was also quantified against the enterohemorrhagic serotype 0157:H7, capable to produce one or more Shiga, and Klebsiella spp., toxins, alone or combined with E.coli.
  • the above-cited strain Lactobacillus plantarum LP01 was positively selected, which is able to establish a barrier-type action against both £. coli and Klebsiella.
  • the microorganism Lactobacillus paracasei LPC09 is capable to create a barrier effect to oxalates, ensuring the complete tolerability of the Cranberry extract even in subjects particularly sensitive to small concentrations of these potential inflammatory agents of the intestinal and urinary mucosae.
  • the composition primarily acts by establishing a physical-mechanical hindrance capable to reduce the urothelium adhesion of Escherichia coli, which is the main cause of bladder infections and inflammations (cystitis). Furthermore, the presence of the specific muco-adhesive gelling complex comprised of tara gum and exopolysaccharides (EPS) produced in situ by S.
  • EPS exopolysaccharides
  • thermophilus ST10 mediates an enhancement of the physical- mechanical hindrance mediated by combining Cranberry and D-mannose, with a barrier-type action even at intestinal level against £ coli and of the possible translocation of pathogenic microorganisms through the intestinal wall.
  • Urinary tract infections are known to be the most common bacterial infection in women. Most of the UTI are uncomplicated acute cystitis caused by Escherichia coli (86%).
  • the present in vivo study carried out by the Applicant was conducted for assessing the efficacy of a composition comprising a dry cranberry extract, D- mannose, a gelling complex comprised of exopolysaccharides (EPS) produced by Streptococcus thermophilus ST10 (DSM 25246) and tara gum, as well as the two microorganisms Lactobacillus plantarum LP01 (LMG P- 21021) and Lactobacillus paracasei LPC09 (DSM 24243) in women with uncomplicated acute cystitis.
  • EPS exopolysaccharides
  • composition 2.5x10 9 of viable cells of the strain of bacterium Lactobacillus plantarum LMG P-21021 (LP01), 1x10 9 of viable cells of the strain of bacterium Lactobacillus paracasei DSM 24243 (LPC09) and 1x10 9 of viable cells of the strain of bacterium S. thermophilus DSM 25246 (ST10) along with 250 mg of tara gum, 500 mg of a Cranberry extract PACs (Naturex SA, Avignon, France) and 250 mg of D-mannose (Hebei Huaxu Pharmaceutical Co., Shijiazhuang, China).
  • the present pilot study demonstrates the long-term ability of a combination of dry cranberry extract, D-mannose, a gelling complex comprised of exopolysaccharides (EPS) produced by S. thermophilus ST10 and tara gum as well as the two microorganisms L plantarum LP01 and L paracasei LPC09, to significantly ameliorate the annoying symptoms reported by women with acute cystitis.
  • EPS exopolysaccharides
  • paracasei LPC09 is effectively able to metabolize oxalates in vitro, thus providing a potential protection against the risk of intestinal inflammation deriving from a prolonged supplementation with a dry cranberry extract.
  • the gelling complex comprising tara gum and S. thermophilus ST10 is able to prolong the mechanical barrier effect usually ensured by the gum throughout the intestine, thus protecting the organism against a possible onset or maintenance of a low-level chronic inflammatory condition.
  • a test with a urine-reactive stick was used together with the assessment of the symptoms for diagnosing UTI and quantifying the efficacy of the tested composition.
  • the convenience and inexpensiveness of the assessment with a urine-reactive stick allowed it to be a common diagnostic tool, and represents a suitable option to urine analysis and urine microscopy for diagnosing uncomplicated acute cystitis.
  • the combination of the positive results obtained with reactive stick, in particular nitrite test, with the symptoms increases the post-test probability of UTI.
  • the presence of nitrites and leukocyte esterase in urine samples were considered as prominent factors for confirming (both positive) and excluding (both negative) an UTI.
  • a reactive stick positive for leukocyte esterase or nitrite and negative for the other one provides a non-definitive diagnostic information and in these patients is thus needed a further assessment.
  • composition No.1 dose 2325 mg
  • sachet granules Example of composition No.1 (dose 2325 mg) in sachet granules:
  • Lactobacillus plantarum LP01 (LMG P-21021) 125 mg (2.5x10 9 CFU/dose)
  • Lactobacillus paracasei LPC09 (DSM 24243) 50 mg (1x10 9 CFU/dose)
  • Natural flavor cranberry; anti-caking agent silicon dioxide; black carrot anthocyanins; sucralose.
  • composition No.2 dose 2575 mg
  • sachet granules Example of composition No.2 (dose 2575 mg) in sachet granules:
  • Lactobacillus plantarum LP01 (LMG P-21021) 125 mg (2.5x10 9 CFU/dose)
  • Natural flavor cranberry; anti-caking agent silicon dioxide; black carrot anthocyanins; sucralose.
  • composition No.3 dose 2575 mg
  • sachet granules Example of composition No.3 (dose 2575 mg) in sachet granules:
  • Lactobacillus plantarum LP01 (LMG P-21021) 125 mg (2.5x10 9 CFU/dose)
  • Natural flavor cranberry; anti-caking agent silicon dioxide; black carrot anthocyanins; sucralose.
  • Lactobacillus plantarum LP01 (LMG P-21021) 125 mg (2.5x10 9 CFU/dose)
  • Natural flavor cranberry Natural flavor cranberry; anti-caking agent: silicon dioxide; black carrot anthocyanins; sucralose.
  • composition (5-8) correspond to compositions (1-4) wherein the strain of bacteria Lactobacillus plantarum LP01 (LMG P-21021) is replaced by the strain of bacteria Lactobacillus plantarum LP02 (LMG P- 21020) and the strain of bacteria Lactobacillus paracasei LPC09 (DSM 24243) is replaced by the strain of bacteria Lactobacillus acidophilus DSM 21717 -LA02.
  • composition of the present invention can be in solid form, for oral use, as tablet, capsule, granules or powder.
  • compositions the present invention for example in the form of granules for oral use in sachet, have a shelf- life of at least 3.5x10 9 viable cells at 24 months and at 25°C. It is recommended to take 2 sachets per day during the first 4 weeks, than to continue, for maintenance purposes, with 1 sachet per day over even long periods.
  • the compositions of the present invention are well tolerated by the organism and thus allow a continuous and prolonged use over the time without side effects.
  • FIG. 1 Cytokine profile. Mean ⁇ S.E.M. of 10 independent experiments. The statistical meaning is calculated by using the Student ' s f-test. When it is calculated relative to the basal conditions (non-stimulated PBMC), the values p ⁇ 0.05 are considered statistically significant.
  • the IL-10 production was assessed in the culture supernatant after one day from stimulation.
  • the IL-4 production was assessed in the culture supernatant after five days of stimulation. Similar results were obtained with the strain Lactobacillus plantarum LMG P-21020 -LP02.
  • Figure 1 relates to the quantification of E.coli (ATCC 8739, ATCC 10536, ATCC 35218, ATCC 25922) inhibition by the strain Lactobacillus plantarum LMG P-21021 -LP01.
  • Figure B relates to the quantification of E.coli (ATCC 8739, ATCC 10536, ATCC 35218, ATCC 25922) inhibition by the strain Lactobacillus plantarum LMG P-21020 -LP02.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Urology & Nephrology (AREA)
  • Epidemiology (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Botany (AREA)
  • Medical Informatics (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Biomedical Technology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Virology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)

Abstract

The present invention relates to a composition comprising lactic bacteria for use in the preventive and/or curative treatment of bacterial infections, which cause urinary tract and/or bladder inflammations, in particular for the treatment of recurrent cystitis.

Description

COMPOSITION COMPRISING LACTIC ACID BACTERIA FOR USE IN THE PREVENTIVE AND/OR CURATIVE TREATMENT OF RECURRENT CYSTITIS
The present invention relates to a composition comprising lactic bacteria for use in the preventive and/or curative treatment of bacterial infections and related inflammations of the urinary tract and/or bladder, in particular for the treatment of recurrent cystitis.
Pathogenic bacteria belonging to the species Escherichia coii are known to be able to adhere to the epithelial cell surface of the urinary bladder (urothelium). For this and other reasons, it is known that pathogenic bacteria belonging to the species Escherichia coii are responsible for more than 80% of the cases of bacterial infections, which cause bladder inflammations (cystitis). Cystitis, in particular recurrent cystitis, causes discomfort and pain, at times even in acute form.
In view of the above, there is a need to intervene both against bacterial infections caused by E.coli and the related inflammations of the urinary tract and/or bladder.
Therefore, there is a need to efficiently intervene against pathogens belonging to the species Escherichia coii both through a barrier effect, in order to reduce the adhesion of the pathogen itself to the epithelial cells of the urinary bladder, and through an anti-Eco// activity, for hindering the development and proliferation of the pathogen itself. In particular, there is a need to have a treatment for preventing and/or curing cystitis, in particular recurrent cystitis, by adopting a treatment compatible with the physiological habitat and which is well tolerated so that to be administered for a continuous use without side effects. Finally, there is a need to have a natural and effective barrier effect, in the case of both an acute episode and possible relapses, which continues over the time for ensuring a long-term protection and assuring a long-lasting effective preventive and/or curative treatment.
The Applicant, following to an extended and intense research activity, gave a response to the above-cited needs. In fact, the Applicant, after testing and studying many strains of lactic bacteria, succeeded to select only some of them. The selected strains have, at the same time, an activity against the pathogenic bacteria E.coli which cause infections and a high anti-inflammatory activity since they are strains of bacteria producing interleukin 4 (IL-4) and interleukin 10 (IL-10).
It is an object of the present invention a composition for use in the preventive and/or curative treatment of bacterial infections and related inflammations of the urinary tract and/or bladder, having the characteristics as disclosed in the appended claim. Said composition is preferably for use in the preventive and/or curative treatment of cystitis, in particular recurrent cystitis.
By preventive and/or curative treatment is meant to also include circumstances wherein the urinary tract and/or bladder inflammation is limited, reduced or attenuated, which improve the health conditions of the subject being treated.
Preferred embodiments of the present invention are contemplated in the following detailed description.
In the context of the present invention by composition is meant to include a pharmaceutical composition, or a supplement product or a medical device or a food composition.
It is an object of the present invention a composition comprising a mixture of bacteria which comprises or, alternatively, consists of: strains of bacteria having both a specific antibacterial activity against E.coli and an antiinflammatory activity with stimulation of the Interleukin IL-4 and Interleukin IL-10 production, and strains of bacteria having an oxalate-degrading activity.
It is an object of the present invention a composition wherein said mixture comprises or, alternatively, consists of: at least a strain of bacteria having both a specific antibacterial activity against E.coli and an anti-inflammatory activity with stimulation of the Interleukin IL-4 and Interleukin IL-10 production, combined with at least a strain of bacteria having an oxalate-degrading activity.
It is an object of the present invention a composition comprising or, alternatively, consisting of a mixture of bacteria which comprises or, alternatively, consists of at least a strain of bacteria selected from the group comprising the strain Lactobacillus plantarum LMG P-21021 -LP01 and the strain Lactobacillus plantarum LMG P-21020 -LP02, combined with at least a strain of bacteria selected from the group comprising the strain Lactobacillus paracasei DS 24243 -LPC09, the strain Lactobacillus gasseri DSM 18299 -LGS01 , the strain Lactobacillus gasseri DSM 18300 -LGS02, the strain Lactobacillus acidophilus DSM 24303 -LA07 and the strain Lactobacillus acidophilus DSM 21717 -LA02, for use in the preventive and/or curative treatment of bacterial infections and related inflammations of the urinary tract and/or bladder.
The strain Lactobacillus plantarum LMG P-21021 -LP01 was deposited by Mofin Sri Company on 16.10.2001 at the BCCM LMG center. The strain Lactobacillus plantarum LMG P-21020 -LP02 was deposited by Mofin Sri Company on 16.10.2001 at the BCCM LMG center.
The strain Lactobacillus paracasei DSM 24243 -LPC09 was deposited by Probiotical S.p.A. Company on 23.11.2010 at the DSMZ center.
The strain Lactobacillus gasseri DSM 18299 -LGS01 was deposited by Anidral Sri Company, now Probiotical S.p.A., on 24.05.2006 at the DSMZ center.
The strain Lactobacillus gasseri DSM 18300 -LGS02 was deposited by Anidral Sri Company, now Probiotical S.p.A., on 24.05.2006 at the DSMZ center.
The strain Lactobacillus acidophilus DSM 24303 -LA07 was deposited by Probiotical S.p.A. Company on 23,11.2010 at the DSMZ center.
The strain Lactobacillus acidophilus DSM 21717 -LA02 was deposited by Probiotical S.p.A. Company on 06.08.2008 at the DSMZ center.
In a preferred embodiment, the composition comprises or, alternatively, consists of a mixture of bacteria which comprises or, alternatively, consists of Lactobacillus plantarum LMG P-21021 -LP01 combined with at least a strain of bacteria selected from the group comprising the strain Lactobacillus paracasei DSM 24243 -LPC09, the strain Lactobacillus gasseri DSM 18299 -LGS01 , the strain Lactobacillus gasseri DSM 18300 -LGS02, the strain Lactobacillus acidophilus DSM 24303 -LA07 and the strain Lactobacillus acidophilus DSM 21717 -LA02; preferably in a weight ratio comprised from 4:1 to 3:1; even more preferably 1 :1. Said compositions are for use in the preventive and/or curative treatment of cystitis, in particular of recurrent cystitis.
In another preferred embodiment, the composition comprises or, alternatively, consists of a mixture of bacteria which comprises or, alternatively, consists of Lactobacillus plantarum LMG P-21020 -LP02 combined with at least a strain of bacteria selected from the group comprising the strain Lactobacillus paracasei DSM 24243 -LPC09, the strain Lactobacillus gasseri DSM 18299 -LGS01 , the strain Lactobacillus gasseri DSM 18300 -LGS02, the strain Lactobacillus acidophilus DSM 24303 -LA07 and the strain Lactobacillus acidophilus DSM 21717 -LA02; preferably in a weight ratio comprised from 4:1 to 3:1 ; even more preferably 1 :1. Preferably, said compositions are for use in the preventive and/or curative treatment of cystitis, in particular of recurrent cystitis. Said compositions can further comprise a cranberry extract, preferably a dry cranberry extract, and/or can further comprise a D-mannose.
In another preferred embodiment, said compositions can comprise, in addition to the strains of bacteria described above and the amounts disclosed above, a cranberry extract, preferably a dry cranberry extract; and/or can comprise a D-mannose; and/or can comprise a plant gum and/or a plant gelatin. The plant gum and/or the plant gelatin is preferably selected from the group comprising a tannate or a gelatin tannate, an alginate, a xyloglucan or xylogel, a guar gum, a tara gum, an acacia, carob, oat, bamboo fiber, citrus fruit fibers and glucomannans. Preferably it is a guar gum. The selected plant gum and/or plant gelatin reduces the bacterial translocation of E.coli from the intestine to the bladder.
Preferably, all the above-described compositions can further comprise a fiber with prebiotic activity selected from inulin, fructo-oligosaccharides (FOS), galacto- and trans-galacto-oligosaccharides (GOS and TOS), gluco- oligosaccharides (GOSa), xylo-oligosaccharides, (XOS), chitosan-oligosaccharides (COS), soy-oligosaccharides (SOS), isomalto-oligosaccharides (IMOS), resistant starch, pectins, psyllium, arabino-galactans, gluco-mannans and galacto-mannans.
In a preferred embodiment, the composition of the present invention comprises or, alternatively, consists of:
(i) a mixture of bacteria which comprises or, alternatively, consists of Lactobacillus plantarum LMG P-21021 - LP01 and Lactobacillus paracasei DSM 24243 -LPC09; preferably in a weight ratio comprised from 4:1 to 3:1 ; even more preferably 1 :1 ,
(ii) a cranberry extract, preferably a dry cranberry extract, a D-mannose and
a guar gum; preferably in a weight ratio 1 :1 :1 , and
(iii) a fructo-oligosaccharide -FOS; preferably in a weight ratio 5:1 relative to the weight of cranberry extract.
In another preferred embodiment, the composition of the present invention comprises or, alternatively, consists of:
(i) a mixture of bacteria which comprises or, alternatively, consists of Lactobacillus plantarum LMG P-21020 - LP02 and Lactobacillus acidophilus DSM 21717 -LA02; preferably in a weight ratio comprised from 4:1 to 3:1 ; even more preferably 1 :1 ,
(ii) a cranberry extract, preferably a dry cranberry extract, a D-mannose and
a guar gum; preferably in a weight ratio 1 :1 :1 , and
(iii) a fructo-oligosaccharide -FOS; preferably in a weight ratio 5:1 relative to the weight of cranberry extract.
The composition of the present invention due to the presence of a cranberry extract, preferably a dry extract (trade name PACran®, a dry extract of US cranberry (Cranberry -Vaccinium macrocarpon- extract)) is able to establishing a physical-mechanical hindrance against the Escherichia coli adhesion to the epithelial cell surface of the urinary bladder (urothelium).
The activity of said cranberry extract is mediated, in particular, by the proanthocyanidin subtraction with the trimers and tetramers characterized by A-type bonds which compete with the adhesins located on the P-type fimbriae (FimH, mannose-sensitive) which uses £. coli for mediating its anchoring to the epithelial cells through specific receptors, thereby hindering in a physical-mechanical manner its adhesion and subsequent bladder colonization.
Advantageously, the strain of bacteria Lactobacillus plantarum LMG P-21021 - LP01 and/or the strain of bacteria Lactobacillus plantarum LMG P-21020 -LP02, in the presence of the cranberry extract, are able to complement and enhance the physical-mechanical hindrance exerted by the cranberry extract as described above, through a barrier-type action even at intestinal level against £ coli. These two strains of bacteria Lactobacillus plantarum LMG P-21021 - LP01 and Lactobacillus plantarum LMG P-21020 -LP02 have a proven E.coli activity and a high anti-inflammatory activity since they produce interleukin 4 (IL-4) and interleukin 10 (IL-10).
Preferably, the strain of bacteria Lactobacillus plantarum LMG P-21021 - LP01 and/or the strain of bacteria Lactobacillus plantarum LMG P-21020 -LP02 are in an amount comprised from 1 to 3 billions of viable cells/dose, even more preferably from 2 to 2.5 billions of viable cells/dose.
The strains of bacteria of the present invention exert a marked barrier-type action against potential Gram- negative pathogens, with particular reference to the species Escherichia coli and a high anti-inflammatory activity since they produce interleukin 4 (IL-4) and interleukin 10 (IL-10).
Advantageously, the strains of bacteria Lactobacillus paracasei DSM 24243 -LPC09, Lactobacillus gasseri DSM 18299 -LGS01 , Lactobacillus gasseri DSM 18300 -LGS02, Lactobacillus acidophilus DSM 24303 -LA07 and Lactobacillus acidophilus DSM 21717 -LA02 are able to carry out a protective action since they exert a barrier effect to the oxalates contained in the cranberry extract, preferably in the form of dry extract. The metabolization of these oxalate molecules prevents the intestinal accumulation and the systemic absorption thereof, thus avoiding the establishment and the maintenance of an inflammatory condition of the intestine, particularly disadvantageous in the occurrence of diverticula.
The strains of bacteria Lactobacillus paracasei DSM 24243 -LPC09, Lactobacillus gasseri DSM 18299 -LGS01, Lactobacillus gasseri DSM 18300 -LGS02, Lactobacillus acidophilus DSM 24303 -LA07 and Lactobacillus acidophilus DSM 21717 -LA02 metabolize the oxalates and, therefore, have a proved anti-renal gravel activity. These strains of bacteria prevent the renal accumulation of oxalates thus avoiding the renal gravel formation and, thereby, impeding the establishment and the maintenance of an inflammatory condition of the urinary tract particularly disadvantageous for the health status of a bladder subjected to recurrent cystitis.
The percentage of oxalate degradation is as follows:
- Lactobacillus paracasei DSM 24243 -LPC09, greater than 68%;
- Lactobacillus gasseri DSM 18299 -LGS01 , greater than 68%;
- Lactobacillus gasseri DSM 18300 -LGS02, greater than 66%;
- Lactobacillus acidophilus DSM 24303 -LA07, greater than 54%;
- Lactobacillus acidophilus DSM 21717 -LA02, greater than 50%.
The presence of strains of bacteria degrading oxalates in the composition of the present invention is also important for the following reason. The cranberry extract contains a fair oxalate amount. A prolonged use of cranberry extract could lead to renal gravel formation, which may force the subject to suspend the use thereof. The use of strains degrading oxalates of the present invention prevents this drawback allowing a prolonged administration of cranberry extract.
Preferably, the strains of bacteria Lactobacillus paracasei DSM 24243 -LPC09, Lactobacillus gasseri DSM 18299 -LGS01 , Lactobacillus gasseri DSM 18300 -LGS02, Lactobacillus acidophilus DSM 24303 -LA07 and Lactobacillus acidophilus DSM 21717 -LA02 are in an amount comprised from 0.5 to 2 billions of viable cells/dose, even more preferably from 1 to 1.5 billions of viable cells/dose.
The composition further comprises D-mannose, which enhances the barrier effect exerted by the cranberry extract. In particular, D-mannose in a simple sugar, namely a monosaccharide which, once absorbed in the blood circulation, is neither transformed in glycogen nor exploited by the organism, with a subsequent removal by the kidney and achievement of high concentrations in the urinary tract wherein it will exert its hindering effects against the bacteria being present. In fact, D-mannose has a high affinity for mannose-sensitive lectins, typical proteins of cell membranes of the human organism used by many bacteria for adhering to the urinary mucosae. Additionally, D-mannose also exerts a mechanical action, which inhibits the formation of biofilms that many bacteria are able to produce with the dual purpose of protecting from our immune system elements and from antibiotics, as well as more effectively adhering to the mucosal surface.
The composition of the present invention can further comprise at least a gum, among those described above, which decreases the bacterial translocation of E.coli from the intestine to the bladder. The gum can be a plant gum and/or a plant gelatin. The plant gum and/or the plant gelatin is preferably selected from the group comprising a tannate or a gelatin tannate, an alginate, a xyloglucan or xylogel, a guar gum, a tara gum, an acacia, carob, oat, bamboo fiber, citrus fruit fibers and glucomannans. Preferably it is a guar gum. The selected plant gum and/or plant gelatin reduces the bacterial translocation of E.coli from the intestine to the bladder. Preferably it is a guar gum. The guar gum exerts a mechanical action at intestinal level, hindering the adhesion of Escherichia coli and other pathogens to the mucosa of the organ, thus reducing their translocation through the intestinal wall and the subsequent risk of infection of adjacent organs. In particular, the gum acts by forming a hydrophilic gel, which evenly distributes over the mucosal surface, restoring the physiological barrier effect of this organ, which typically results impaired in the event of intestinal infections by Escherichia coli or other pathogens.
In addition, the composition of the present invention further comprises a fiber with prebiotic activity (prebiotic fiber), which can be selected from inulin, fructo-oligosaccharides (FOS), galacto- and trans-galacto- oligosaccharides (GOS and TOS), gluco-oligosaccharides (GOSa), xylo-oligosaccharides, (XOS), chitosan- oligosaccharides (COS), soy-oligosaccharides (SOS), isomalto-oligosaccharides (IMOS), resistant starch, pectins, psyllium, arabino-galactans, gluco-mannans and galacto-mannans. Preferably, it is selected from short chain fructo-oligosaccharides (FOSsc) or galactooligosaccharides GOS which contributes to the growing and replication of the bacterial strains existing in the composition.
The composition of the present invention can further comprise excipients selected from natural flavors, anti- caking agents such as silicon dioxide, black carrot anthocyanins, sucralose.
The mixture of bacteria has a bacterial load comprised from 1x108 to 1x1012 CFU/g of mixture. The composition of the present invention which contains said mixture of bacteria has a bacterial load of about 5x107-5x109 CFU/composition.
It is an object of the present invention a composition comprising a mixture, which comprises or, alternatively, consists of:
- (a) a strain of bacterium Lactobacillus plantarum LP01 (LMG P-21021) and/or
- (b) a strain of bacterium Lactobacillus paracasei LPC09 (DSM 24343); said composition further comprises:
- (c) a specific muco-adhesive gelling complex, comprised of EPS, exopolysaccharides of bacterial origin (produced by Streptococcus thermophilus ST10 DSM 25246 and tara gum, a polysaccharide of plant origin. Said gelling complex is able to establish a mechanical barrier effect throughout the gastro-intestinal tract. Said composition further contains (d) a specific dry extract of US cranberry (Cranberry - PACran®) and (e) a suitable amount of D-mannose (composition). Due to the presence of cranberry and D-mannose the composition is able to establishing a hindering action of physical-mechanical type against the adhesion of Escherichia coli to the epithelial cell surface of the urinary bladder, responsible for most of the cases of bacterial infections which cause inflammations of this organ (cystitis).
Due to the presence of the specific ingredient PACran®, a dry extract of US cranberry (Cranberry, Vaccinium macrocarpon), the composition is able to establish a natural physical-mechanical hindrance against the adhesion of Escherichia coli to the epithelial cell surface of bladder and urinary tract. Its main activity is related to the proanthocyanidin subfraction (phytochemical component of fruits) containing trace elements which compete with the adhesins located on the P-type fimbriae (Fim H, mannose-sensitive) which uses E. coli for mediating its anchoring to the epithelial cells, thereby hindering in a physical-mechanical manner its adhesion and subsequent colonization of urinary tract and bladder,
Such a barrier is further enhanced due to the present of D-mannose, a simple sugar. UPEC bacteria, by binding the D-mannose molecules through the P-type fimbriae, remain in free form in the urine and, thus, are more easily removed by urination. Finally, D-mannose exerts a mechanical action inhibiting the formation of biofilms that many bacteria are able to produce. After exerting its hindering effect, D-mannose is able to bind the cells of the bladder mucosa (of which is constitutive part) restoring a protective layer similar to the physiological one comprised of glycosaminoglycans, which is usually damaged by recurrent inflammations.
The composition further comprises a suitable amount of tara gum which, due to its gelling and muco-adhesive properties, is capable to form a hydrogel within few minutes after ingestion, by virtue of its thixotropic characteristics, thereby creating, in the first part of the gastrointestinal tract a mechanical barrier action against the adhesion of Escherichia coli and other pathogens to the mucosa of the organ, thus reducing the translocation thereof through the intestinal wall and the subsequent risk of infection of adjacent organs, among which mainly the bladder. Such a barrier effect is completed and extended throughout the gastro-intestinal tract by the presence of exopolysaccharides (EPS), produced in situ by the microorganism Streptococcus thermophilus ST10, which thereby enhance the viscosity of the surrounding environment through a self-regulated, and exclusively mechanical mechanism. The ingestion of the above cited bacterium carries in the human intestine a source of molecules with gelling activity, thus exerting an action totally complementary to that of tara gum.
The above-cited muco-adhesive gelling complex has an innovative property which has to be taken into account: tara gum, like ail the gums of plant origin, is progressively degraded by the resident microbiota during its intestinal transit, thereby progressively reducing its gelling power of mechanical hindrance. The gradual reduction of the plant gum action is effectively counterbalanced by the gradual increase of exopolysaccharide (EPS) release in the intestinal lumen by the bacterial strain ST10, which exerts its property mainly in ileum and colon. The synergistic combination of tara gum and exopolysaccharides (EPS) thereby ensures the presence of gelling molecules throughout the gastro-intestinal tract, maximizing and optimizing the mechanical barrier action of the product. The presence, production and retention of the hydrophilic gel in the lumen of the organ can, therefore, be considered for the first time really complete, with a first area wherein the plant gum action is maximum and a second area wherein the exopoiysaccharide (EPS) action is maximum.
The two microorganisms Lactobacillus plantarum LP01 (LMG P-21021) (for example 2.5 billions/daily dose) and Lactobacillus paracasei LPC09 (DSM 24343) (for example 1 billion/daily dose), mediate an enhancement of the barrier effect established by the muco-adhesive gelling complex comprised of tara gum and exopolysaccharides (EPS), by a barrier-type action against £ coli even at intestinal level. The Applicant carried out a selection of microorganisms with a marked barrier-type action against potential Gram-negative pathogens, with particular reference to the species Escherichia coli, the main role of which in cystitis has been well demonstrated. In addition to the 4 strains of £. coli deriving from the ATCC Collection, the barrier action was also quantified against the enterohemorrhagic serotype 0157:H7, capable to produce one or more Shiga, and Klebsiella spp., toxins, alone or combined with E.coli. Following to this research activity, the above-cited strain Lactobacillus plantarum LP01 was positively selected, which is able to establish a barrier-type action against both £. coli and Klebsiella. Furthermore, the microorganism Lactobacillus paracasei LPC09 is capable to create a barrier effect to oxalates, ensuring the complete tolerability of the Cranberry extract even in subjects particularly sensitive to small concentrations of these potential inflammatory agents of the intestinal and urinary mucosae.
Thus, it can be concluded that the composition primarily acts by establishing a physical-mechanical hindrance capable to reduce the urothelium adhesion of Escherichia coli, which is the main cause of bladder infections and inflammations (cystitis). Furthermore, the presence of the specific muco-adhesive gelling complex comprised of tara gum and exopolysaccharides (EPS) produced in situ by S. thermophilus ST10, as well as of the two microorganisms L plantarum LP01 and L paracasei LPC09, mediates an enhancement of the physical- mechanical hindrance mediated by combining Cranberry and D-mannose, with a barrier-type action even at intestinal level against £ coli and of the possible translocation of pathogenic microorganisms through the intestinal wall.
Urinary tract infections (UTI) are known to be the most common bacterial infection in women. Most of the UTI are uncomplicated acute cystitis caused by Escherichia coli (86%). The present in vivo study carried out by the Applicant was conducted for assessing the efficacy of a composition comprising a dry cranberry extract, D- mannose, a gelling complex comprised of exopolysaccharides (EPS) produced by Streptococcus thermophilus ST10 (DSM 25246) and tara gum, as well as the two microorganisms Lactobacillus plantarum LP01 (LMG P- 21021) and Lactobacillus paracasei LPC09 (DSM 24243) in women with uncomplicated acute cystitis.
The following composition was tested: 2.5x109 of viable cells of the strain of bacterium Lactobacillus plantarum LMG P-21021 (LP01), 1x109 of viable cells of the strain of bacterium Lactobacillus paracasei DSM 24243 (LPC09) and 1x109 of viable cells of the strain of bacterium S. thermophilus DSM 25246 (ST10) along with 250 mg of tara gum, 500 mg of a Cranberry extract PACs (Naturex SA, Avignon, France) and 250 mg of D-mannose (Hebei Huaxu Pharmaceutical Co., Shijiazhuang, China).
Methods. 33 premenopausal and non-pregnant women diagnosed with uncomplicated acute cystitis were enrolled in a prospective pilot study and completed the treatment protocol. The subjects were instructed to take two doses per day for the first month, than to continue with 1 sachet per day until the sixtieth day. Nitrites and leukocyte esterase through assessment with urine-reactive stick were used as markers of cystitis, with an analysis carried out at the beginning, after 30 and 60 days, and after one month of follow-up. The typical symptoms of UTI, namely dysuria, frequent emptying of small volumes, urinary urgency, suprapubic pain and macroscopic haematuria were scored 0-3 and assessed during each medical examination.
Results. Positive results for the presence of nitrites and leukocyte esterase were respectively detected in 14 and 20 subjects after 30 days and in 9 and 14 women after 60 days (p < 0.001). At the end of the follow-up period, positive results for nitrites and leukocyte esterase were recorded only in 4 and 3 of the 24 and 19 subjects (respectively 16.7%, p = 0.103; 15.8%, p = 0.325) with negative results after 60 days. The typical symptoms of cystitis, specifically, dysuria, frequent emptying, urgency and suprapubic pain were also significantly ameliorated. No significant differences were recorded for the incidence and severity of haematuria in any medical examination. The present study substantiates the efficacy of the tested composition based on cranberry, D-mannose, an innovative gelling complex and the two microorganisms in significantly ameliorating the annoying symptoms reported by women with acute cystitis.
The present pilot study demonstrates the long-term ability of a combination of dry cranberry extract, D-mannose, a gelling complex comprised of exopolysaccharides (EPS) produced by S. thermophilus ST10 and tara gum as well as the two microorganisms L plantarum LP01 and L paracasei LPC09, to significantly ameliorate the annoying symptoms reported by women with acute cystitis. To our knowledge, this is the first study which assesses the efficacy of a combination of lactobacilli with a dry cranberry extract in women with uncomplicated acute cystitis. A relatively low number of relapses was recorded during the first month of follow-up according to the considered parameters, thus suggesting the long-term barrier effect exerted by the product. The acceptance and global tolerability profile were very good, since only two exclusions were recorded during the first and second months of treatment due to a deviation from the protocol and no significant negative events occurred. Cranberry {Vaccinium macrocarpon extract) and D-mannose have both an efficacy in hindering, also mechanically, the adhesion of strains of E. coli to the urotheiium, the epithelium lining most of the urinary tract. This test can represent a natural tool intended for progressively reducing the severity of a cystitis, thus contributing in alleviating the related symptoms. In any case, cranberries have a relatively high content of oxalic acid, a substance which should be avoided by individuals with a tendency to form calcium oxalate renal stones. The strain L. paracasei LPC09 is effectively able to metabolize oxalates in vitro, thus providing a potential protection against the risk of intestinal inflammation deriving from a prolonged supplementation with a dry cranberry extract. The gelling complex comprising tara gum and S. thermophilus ST10 is able to prolong the mechanical barrier effect usually ensured by the gum throughout the intestine, thus protecting the organism against a possible onset or maintenance of a low-level chronic inflammatory condition.
In the present study, a test with a urine-reactive stick was used together with the assessment of the symptoms for diagnosing UTI and quantifying the efficacy of the tested composition. The convenience and inexpensiveness of the assessment with a urine-reactive stick, allowed it to be a common diagnostic tool, and represents a suitable option to urine analysis and urine microscopy for diagnosing uncomplicated acute cystitis. Furthermore, it is known that the combination of the positive results obtained with reactive stick, in particular nitrite test, with the symptoms, increases the post-test probability of UTI. In particular, the presence of nitrites and leukocyte esterase in urine samples were considered as prominent factors for confirming (both positive) and excluding (both negative) an UTI. In fact, a reactive stick positive for leukocyte esterase or nitrite and negative for the other one, provides a non-definitive diagnostic information and in these patients is thus needed a further assessment.
Usually, no nitrite is detectable in the urine. Many enteric Gram-negative bacteria such as coliforms are able to synthetizing nitrite, thereby allowing the detection of their presence by means of a simple test. On the other hand, a leukocyte increase indicates pyuria and it is detected in almost all the renal and urinary tract diseases. Leukocyte esterase is a reliable marker for leukocytes in the urine. Urine cultures are recommended only for patients with suspected acute pyelonephritis, patients with symptoms without resolution or with relapse within from two to four weeks after the completion of the treatment and patients with atypical symptoms.
A simultaneous reduction of the incidence of positive results for nitrites and leukocyte esterase and the severity of the UTI symptoms was recorded, with particular reference to dysuria, frequent emptying, urgency and suprapubic pain. It has to be noted that haematuria maintained almost unchanged throughout the study, probably because a longer period is required for obtaining the urotheiium healing and becoming clinically obvious.
In any case, the results obtained from the present study are positive and encouraging.
Example of composition No.1 (dose 2325 mg) in sachet granules:
Ingredients
- Cranberry extract (Cranberry PACran®) 250 mg/dose
- D-Mannose 250 mg
- Lactobacillus plantarum LP01 (LMG P-21021) 125 mg (2.5x109 CFU/dose) - Lactobacillus paracasei LPC09 (DSM 24243) 50 mg (1x109 CFU/dose)
- Short chain fructo-oligosaccharides -FOSsc 1250 mg/dose
Excipients (400 mg/dose)
Natural flavor cranberry; anti-caking agent: silicon dioxide; black carrot anthocyanins; sucralose.
Example of composition No.2 (dose 2575 mg) in sachet granules:
Ingredients
- Cranberry extract (Cranberry PACran®) 250 mg/dose
- D-Mannose 250 mg
- Lactobacillus plantarum LP01 (LMG P-21021) 125 mg (2.5x109 CFU/dose)
- Lactobacillus paracasei LPC09 (DSM 24243) 50 mg (1x109 CFU/dose)
- Short chain fructo-oligosaccharides -FOSsc 1250 mg/dose
- guar gum 250 mg/dose
Excipients (400 mg/dose)
Natural flavor cranberry; anti-caking agent: silicon dioxide; black carrot anthocyanins; sucralose.
Example of composition No.3 (dose 2575 mg) in sachet granules:
Ingredients
- Cranberry extract (Cranberry PACran®) 500 mg/dose
- D-Mannose 250 mg
- Lactobacillus plantarum LP01 (LMG P-21021) 125 mg (2.5x109 CFU/dose)
- Lactobacillus paracasei LPC09 (DSM 24243) 50 mg (1x109 CFU/dose)
- Short chain fructo-oligosaccharides -FOSsc 1250 mg/dose
Excipients (400 mg/dose)
Natural flavor cranberry; anti-caking agent: silicon dioxide; black carrot anthocyanins; sucralose.
Example of composition No.4 (dose 2825 mg) in sachet granules:
Ingredients
- Cranberry extract (Cranberry PACran®) 500 mg/dose
- D-Mannose 250 mg
- Lactobacillus plantarum LP01 (LMG P-21021) 125 mg (2.5x109 CFU/dose)
- Lactobacillus paracasei LPC09 (DSM 24243) 50 mg (1x109 CFU/dose)
- Short chain fructo-oligosaccharides -FOSsc 1250 mg/dose
- guar gum 250 mg/dose
Excipients (400 mg/dose) Natural flavor cranberry; anti-caking agent: silicon dioxide; black carrot anthocyanins; sucralose.
Examples of composition (5-8) correspond to compositions (1-4) wherein the strain of bacteria Lactobacillus plantarum LP01 (LMG P-21021) is replaced by the strain of bacteria Lactobacillus plantarum LP02 (LMG P- 21020) and the strain of bacteria Lactobacillus paracasei LPC09 (DSM 24243) is replaced by the strain of bacteria Lactobacillus acidophilus DSM 21717 -LA02.
The composition of the present invention can be in solid form, for oral use, as tablet, capsule, granules or powder.
The compositions the present invention, for example in the form of granules for oral use in sachet, have a shelf- life of at least 3.5x109 viable cells at 24 months and at 25°C. It is recommended to take 2 sachets per day during the first 4 weeks, than to continue, for maintenance purposes, with 1 sachet per day over even long periods. The compositions of the present invention are well tolerated by the organism and thus allow a continuous and prolonged use over the time without side effects.
Cytokines with immunoregulatory action
This study assessed the induction of cytokines IL-4 and IL-10, which represent the main cytokines with immunoregulatory action. As can be seen in figure A, the tested strains of bacteria Lactobacillus plantarum LMG P-21021 -LP01 and Lactobacillus plantarum LMG P-21020 -LP02 are able to inducing a statistically significant growth relative to the basal conditions in both the cytokines.
Figure A. Cytokine profile. Mean ± S.E.M. of 10 independent experiments. The statistical meaning is calculated by using the Student's f-test. When it is calculated relative to the basal conditions (non-stimulated PBMC), the values p<0.05 are considered statistically significant. The IL-10 production was assessed in the culture supernatant after one day from stimulation. The IL-4 production was assessed in the culture supernatant after five days of stimulation. Similar results were obtained with the strain Lactobacillus plantarum LMG P-21020 -LP02.
Figure 1 relates to the quantification of E.coli (ATCC 8739, ATCC 10536, ATCC 35218, ATCC 25922) inhibition by the strain Lactobacillus plantarum LMG P-21021 -LP01.
Figure B relates to the quantification of E.coli (ATCC 8739, ATCC 10536, ATCC 35218, ATCC 25922) inhibition by the strain Lactobacillus plantarum LMG P-21020 -LP02.

Claims

1. A composition comprising a mixture of bacteria, which comprises or, alternatively, consists of:
- at least a strain of bacteria selected from the group comprising the strain Lactobacillus plantarum LMG P-21021 (LP01) and the strain Lactobacillus plantarum LMG P-21020 (LP02), combined with:
- at least a strain of bacteria selected from the group comprising the strain Lactobacillus paracasei DSM 24243 (LPC09), the strain Lactobacillus gasseri DSM 18299 (LGS01 ), the strain Lactobacillus gasseri DSM 18300 (LGS02), the strain Lactobacillus acidophilus DSM 24303 (LA07) and the strain Lactobacillus acidophilus DSM 21717 (LA02)
for use in the preventive and/or curative treatment of infections and/or inflammations of the urinary tract and/or bladder.
2. The composition per use according to claim 1 , wherein said mixture of bacteria comprises or, alternatively, consists of Lactobacillus plantarum LMG P-21021 (LP01) combined with at least a strain of bacteria selected from the group comprising the strain Lactobacillus paracasei DSM 24243 (LPC09), the strain Lactobacillus gasseri DSM 18299 (LGS01), the strain Lactobacillus gasseri DSM 18300 (LGS02), the strain Lactobacillus acidophilus DSM 24303 (LA07) and the strain Lactobacillus acidophilus DSM 21717 (LA02); preferably in a weight ratio comprised from 4:1 to 3:1 ; even more preferably 1 :1.
3. The composition for use according to claim 1 , wherein said mixture of bacteria comprises or, alternatively, consists of Lactobacillus plantarum LMG P-21020 (LP02) combined with at least a strain of bacteria selected from the group comprising the strain Lactobacillus paracasei DSM 24243 (LPC09), the strain Lactobacillus gasseri DSM 18299 (LGS01 ), the strain Lactobacillus gasseri DSM 18300 (LGS02), the strain Lactobacillus acidophilus DSM 24303 (LA079 and the strain Lactobacillus acidophilus DSM 21717 (LA02); preferably in a weight ratio comprised from 4:1 to 3:1 ; even more preferably 1 :1.
4. The composition for use according to any one of the preceding claims, wherein said composition is for use in the preventive and/or curative treatment of cystitis.
5. The composition for use according to claim 4, in the treatment of recurrent cystitis.
6. The composition for use according to any one of the preceding claims, wherein said composition further comprises a cranberry extract, preferably a dry cranberry extract, and/or said composition further comprises a D- mannose.
7. The composition for use according to any one of the preceding claims, wherein said composition further comprises a plant gum and/or a plant gelatin preferably selected from the group comprising a tannate or a gelatin tannate, an alginate, a xyloglucan or xylogel, a guar gum, a tara gum, an acacia, carob, oat, bamboo fiber, citrus fruit fibers and glucomannans; preferably it is a guar gum.
8. The composition for use according to any one of the preceding claims, wherein said composition further comprises a fiber with prebiotic activity selected from inulin, fructo-oligosaccharides (FOS), galacto- and trans- galacto-oligosaccharides (GOS and TOS), gluco-oligosaccharides (GOSa), xylo-oligosaccharides, (XOS), chitosan-oligosaccharides (COS), soy-oligosaccftarides (SOS), isomalto-oligosaccharides (IMOS), resistant starch, pectins, psyllium, arabino-galactans, gluco-mannans and galacto-mannans; preferably it is a fructo- oligosaccharide -FOS, preferably short-chain.
9. The composition for use according to any one of the preceding claims, wherein said composition comprises or, alternatively, consists of:
(i) a mixture of bacteria which comprises or, alternatively, consists of Lactobacillus plantarum LMG P-21021 (LP01) and Lactobacillus paracasei DSM 24243 (LPC09); preferably in a weight ratio comprised from 4:1 to 3:1; even more preferably 1 :1 ,
(ii) a cranberry extract, preferably a dry cranberry extract, a D-mannose and
a guar gum; preferably in a weight ratio 1 :1 :1 , and
(iii) a fructo-oligosaccharide -FOS; preferably in a weight ratio 5:1 relative to the weight of cranberry extract.
10. The composition for use according to any one of the preceding claims, wherein said composition comprises or, alternatively, consists of:
(i) a mixture of bacteria which comprises or, alternatively, consists of Lactobacillus plantarum LMG P-21020 (LP02) and Lactobacillus acidophilus DSM 21717 (LA02); preferably in a weight ratio comprised from 4:1 to 3:1 ; even more preferably 1 :1 ,
(ii) a cranberry extract, preferably a dry cranberry extract, a D-mannose and a guar gum; preferably in a weight ratio 1 :1 :1 , and
(iii) a fructo-oligosaccharide -FOS; preferably in a weight ratio 5:1 relative to the weight of cranberry extract.
11. The composition for use according to any one of the preceding claims, wherein said composition comprises a mixture comprising or, alternatively, consisting of:
- (a) a strain of bacterium Lactobacillus plantarum LP01 (LMG P-21021 ) and/or
- (b) a strain of bacterium Lactobacillus paracasei LPC09 (DSM 24343); said composition further comprises.
- (c) a specific muco-adhesive gelling complex, comprised of EPS, exopolysaccharides of bacterial origin (produced by Streptococcus thermophilus ST10 DSM 25246 and tara gum, and
- (d) a dry extract of US cranberry (Cranberry - PACran®) and
- (f) an amount of D-mannose.
PCT/IB2014/000731 2013-05-14 2014-05-14 Composition comprising lactic acid bacteria for use in the preventive and/or curative treatment of recurrent cystitis WO2014184639A1 (en)

Priority Applications (12)

Application Number Priority Date Filing Date Title
RU2015148750A RU2015148750A (en) 2013-05-14 2014-05-14 COMPOSITION CONTAINING LACTIC-ACID BACTERIA FOR USE IN PREVENTIVE AND / OR CURATIVE TREATMENT OF REFRESHING CYSTITIS
ES14732360T ES2831900T3 (en) 2013-05-14 2014-05-14 Composition comprising lactic acid bacteria for use in the preventive and / or curative treatment of infections and / or inflammations of the urinary tract and / or bladder
JP2016513453A JP6600623B2 (en) 2013-05-14 2014-05-14 Lactic acid bacteria-containing composition for use in preventive and / or therapeutic treatment of recurrent cystitis
CN201480027970.9A CN105377277A (en) 2013-05-14 2014-05-14 Composition comprising lactic acid bacteria for use in the preventive and/or curative treatment of recurrent cystitis
DK14732360.4T DK2996700T3 (en) 2013-05-14 2014-05-14 COMPOSITION INCLUDING LACTIC ACID BACTERIA FOR USE IN THE PREVENTIVE AND / OR HEALING TREATMENT OF INFECTIONS AND / OR INFLAMMATIONS IN THE URINARY ROUTE AND / OR BLADDER
PL14732360T PL2996700T3 (en) 2013-05-14 2014-05-14 Composition comprising lactic acid bacteria for use in the preventive and/or curative treatment of infections and/or inflammations of the urinary tract and/or bladder
BR112015027536A BR112015027536A8 (en) 2013-05-14 2014-05-14 A composition comprising lactic acid bacteria for use in the preventive and / or curative treatment of recurrent cystitis.
EP14732360.4A EP2996700B1 (en) 2013-05-14 2014-05-14 Composition comprising lactic acid bacteria for use in the preventive and/or curative treatment of infections and/or inflammations of the urinary tract and/or bladder
CA2912013A CA2912013A1 (en) 2013-05-14 2014-05-14 Composition comprising lactic acid bacteria for use in the preventive and/or curative treatment of recurrent cystitis
US14/891,306 US11110136B2 (en) 2013-05-14 2014-05-14 Composition comprising lactic acid bacteria for use in the preventive and/or curative treatment of recurrent cystitis
KR1020157035288A KR102261724B1 (en) 2013-05-14 2014-05-14 Composition comprising lactic acid bacteria for use in the preventive and/or curative treatment of recurrent cystitis
US17/230,665 US20210308197A1 (en) 2013-05-14 2021-04-14 Composition comprising lactic acid bacteria for use in the preventive and/or curative treatment of recurrent cystitis

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IT000793A ITMI20130793A1 (en) 2013-05-14 2013-05-14 COMPOSITION INCLUDING LACTIC BACTERIA FOR USE IN THE PREVENTIVE AND / OR CURATIVE TREATMENT OF THE RECURRENT CYCLES.
ITMI2013A000793 2013-05-14

Related Child Applications (2)

Application Number Title Priority Date Filing Date
US14/891,306 A-371-Of-International US11110136B2 (en) 2013-05-14 2014-05-14 Composition comprising lactic acid bacteria for use in the preventive and/or curative treatment of recurrent cystitis
US17/230,665 Division US20210308197A1 (en) 2013-05-14 2021-04-14 Composition comprising lactic acid bacteria for use in the preventive and/or curative treatment of recurrent cystitis

Publications (2)

Publication Number Publication Date
WO2014184639A1 true WO2014184639A1 (en) 2014-11-20
WO2014184639A9 WO2014184639A9 (en) 2015-01-15

Family

ID=48748368

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/IB2014/000731 WO2014184639A1 (en) 2013-05-14 2014-05-14 Composition comprising lactic acid bacteria for use in the preventive and/or curative treatment of recurrent cystitis

Country Status (13)

Country Link
US (2) US11110136B2 (en)
EP (1) EP2996700B1 (en)
JP (1) JP6600623B2 (en)
KR (1) KR102261724B1 (en)
CN (1) CN105377277A (en)
BR (1) BR112015027536A8 (en)
CA (1) CA2912013A1 (en)
DK (1) DK2996700T3 (en)
ES (1) ES2831900T3 (en)
IT (1) ITMI20130793A1 (en)
PL (1) PL2996700T3 (en)
RU (1) RU2015148750A (en)
WO (1) WO2014184639A1 (en)

Cited By (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN104435078A (en) * 2014-12-16 2015-03-25 汤臣倍健股份有限公司 Composition as well as application and preparation thereof
US10293008B2 (en) 2014-08-29 2019-05-21 Sami Labs Limited Process for enhancing the viable counts of lactic acid bacteria and useful compositions thereof
IT201900016850A1 (en) * 2019-09-20 2021-03-20 Sofar Spa Compositions based on bacterial strains and berry extracts and their use as anti-inflammatories
IT201900016865A1 (en) * 2019-09-20 2021-03-20 Sofar Spa Compositions based on bacterial strains and their use as anti-inflammatories
US10982184B2 (en) 2011-05-09 2021-04-20 Probiotical S.P.A. Bacterial strains capable of metabolizing oxalates
IT201900021483A1 (en) * 2019-11-18 2021-05-18 S I I T S R L Servizio Int Imballaggi Termosaldanti Compositions comprising xyloglucan and D-mannose and their use for the treatment of genitourinary tract disorders
US11110136B2 (en) 2013-05-14 2021-09-07 Probiotical S.P.A. Composition comprising lactic acid bacteria for use in the preventive and/or curative treatment of recurrent cystitis
US11110135B2 (en) 2011-05-09 2021-09-07 Probiotical S.P.A. Bacterial strains belonging to the genus Bifidobacterium for use in the treatment of hypercholesterolaemia
US11446340B2 (en) 2011-05-09 2022-09-20 Probiotical S.P.A. Probiotic bacterial strains and symbiotic composition containing the same intended for infant food

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ITMI20111718A1 (en) 2011-09-23 2013-03-24 Probiotical Spa A WATERPROOF MOISTURE AND OXYGEN MATERIAL FOR PACKAGING DIETARY, COSMETIC AND MEDICINAL PRODUCTS.
IT201600122310A1 (en) * 2016-12-01 2018-06-01 Sofar Spa Composition for use in the treatment of bowel disorders
KR20190045027A (en) 2017-10-23 2019-05-02 (주)예스킨 Composition for treating chronic bladder infection
CN108576802B (en) * 2018-03-27 2021-11-16 仙乐健康科技(安徽)有限公司 Composition for maintaining female health
MY183708A (en) * 2018-05-16 2021-03-09 Diamond Star Global Sdn Bhd Hygiene wash
SG11202103567RA (en) * 2018-10-10 2021-05-28 Servatus Ltd Methods of treatment of inflammatory conditions and associated infections
KR102128685B1 (en) 2019-08-23 2020-07-01 (주) 경주제과 Manufacture method of Korean Wheat Potato Bread
IT202000026518A1 (en) * 2020-11-06 2022-05-06 Montefarmaco Otc S P A USE OF A COMBINATION OF LIVE LACTIC ENVIRONMENTS WITH PROBIOTIC ACTION, LONGBERRY EXTRACT AND D-MANNOSE IN POST COITAL CYSTITIS
KR20230054996A (en) 2021-10-18 2023-04-25 원지희 Manufacture method of prune bread
GB202210523D0 (en) * 2022-07-18 2022-08-31 Multigerm Uk Entpr Ltd Probiotic compositions and therapeutic uses thereof

Citations (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000072855A2 (en) * 1999-05-28 2000-12-07 Vsl Pharma Limited Dietary or pharmaceutical composition for use for the prevention or treatment of hyperoxaluria
WO2008038075A2 (en) * 2006-09-27 2008-04-03 Mofin S.R.L. Microbial liquid cultures having high stability and fermentative activity
US20100092440A1 (en) * 2006-11-28 2010-04-15 Probiotical S.P.A. composition for the administration of biologically active principles in gynaecologic and rectal field and uses thereof
WO2010099824A1 (en) * 2009-03-05 2010-09-10 Probiotical S.P.A. Bacteria strains having a high anti-inflammatory activity
WO2010136891A1 (en) * 2009-05-27 2010-12-02 Probiotical S.P.A. Bacteriocin-producing lactobacillus pentosus and the use thereof in food and pharmaceutical compositions
EP2269465A1 (en) * 2006-05-03 2011-01-05 Probiotical S.p.a. Compositions comprising Bifidobacterium adolescentis
EP2338976A1 (en) * 2008-09-30 2011-06-29 Meiji Dairies Corporation Lactic acid bacterium having high oxalic acid decomposition ability
WO2012101500A1 (en) * 2011-01-28 2012-08-02 Probiotical S.P.A. Effervescent composition in solid form for use in vaginal applications for the treatment of vaginal infections
WO2013034975A1 (en) * 2011-09-09 2013-03-14 Probiotical S.P.A. Strains of lactic acid bacteria and/or bifidobacteria inhibiting/reducing the growth of different biotypes of e. coli and different biotypes of clostridia
WO2013034974A1 (en) * 2011-09-09 2013-03-14 Giovanni Mogna Composition comprising n-acetylcysteine and/or microencapsulated gastroprotected lysozyme in association with probiotic bacteria capable of restoring the stomach's own barrier effect which is lost during the pharmacological treatment of gastric hyperacidity
WO2013050831A1 (en) * 2011-05-09 2013-04-11 Probiotical S.P.A. Bacterial strains capable of metabolizing oxalates
EP2626076A1 (en) * 2010-03-08 2013-08-14 Probiotical S.p.a. Composition comprising probiotic bacteria for the treatment of pathologies associated with alterations of the immune system

Family Cites Families (105)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3819838A (en) 1970-08-04 1974-06-25 Bush Boake Allen Ltd Encapsulated flavoring composition
GB1363301A (en) 1971-07-12 1974-08-14 Ilford Ltd Supersensitising combination'
JPS53121949A (en) 1977-03-31 1978-10-24 Yakult Honsha Kk Production of drink and food containing bifidobacterium cells
DE2757370A1 (en) 1977-12-22 1979-07-05 Bayer Ag GAS-TIGHT PLASTIC-ALUMINUM COMPOSITE FILMS
CH637297A5 (en) 1978-12-05 1983-07-29 Nestle Sa MICROBALL COMPRISING A MICROORGANISM AND ITS MANUFACTURING METHOD.
JPS58152809A (en) 1982-03-05 1983-09-10 Eisai Co Ltd Stable foaming vaginal suppository
US4670272A (en) 1985-11-08 1987-06-02 Frito-Lay, Inc. Thermostable creme
DE3685955D1 (en) * 1986-02-06 1992-08-13 Celgene Corp Biosynthese von heteropolysacchariden.
US5413960A (en) 1987-05-01 1995-05-09 Biogaia Ab Antibiotic reuterin
US5343672A (en) 1992-12-01 1994-09-06 Scherer Ltd R P Method for manufacturing freeze dried dosages in a multilaminate blister pack
UA39965C2 (en) 1993-12-03 2001-07-16 Лайфор Леборетріз Лтд VIRUSIC, BACTERICIDAL AND DESTRUCTIVE SPERMATOSES VAGINAL PRODUCT AND VAGINAL SUPPOSITORY (OPTIONS)
CN1211188A (en) 1996-02-14 1999-03-17 普罗克特和甘保尔公司 Urogenital and intestinal compositions
JPH11504049A (en) 1996-02-14 1999-04-06 ザ、プロクター、エンド、ギャンブル、カンパニー Compositions for genitourinary and intestinal disorders, comprising substances from plant species of the azalea family and lactic acid bacterial growth factor
US8828432B2 (en) 1996-10-28 2014-09-09 General Mills, Inc. Embedding and encapsulation of sensitive components into a matrix to obtain discrete controlled release particles
EP0845350A1 (en) 1996-11-29 1998-06-03 Alusuisse Technology &amp; Management AG Cold formable laminated film
WO1998036738A1 (en) 1997-02-20 1998-08-27 Therics, Inc. Dosage form exhibiting rapid disperse properties, methods of use and process for the manufacture of same
FR2765078B1 (en) 1997-06-27 1999-09-17 Guyomarc H Nutrition Animale METHOD FOR IMPROVING THE EFFECTIVENESS OF A PROBIOTIC, PREPARATION OF FOOD ADDITIVES AND ANIMAL FEED CONTAINING IT
ATE314858T1 (en) 1998-04-01 2006-02-15 Ganeden Biotech Inc EXPERIENCE IN REDUCING CHOLESTEROL WITH BACILLUS COAGULANS SPORES, SYSTEMS AND COMPOSITIONS
WO1999055326A1 (en) 1998-04-30 1999-11-04 Vit-Immune, L.C. Method of treatment of glutathione deficient mammals
ATE207755T1 (en) 1998-04-30 2001-11-15 Vesely Renata Maria Cavaliere PHARMACEUTICAL COMPOSITIONS CONTAINING LACTOBACILLUS BREVIS AND LACTOBACILLUS SALIVARIUS FOR THE TREATMENT OF VAGINAL INFECTIONS
EP1137423B1 (en) 1998-12-11 2005-03-09 Urex Biotech, Inc. Oral administration of lactobacillus for the treatment and prevention of urogenital infection
RU2150268C1 (en) 1998-12-25 2000-06-10 Быков Валерий Алексеевич Lactobacterium-containing suppository for treatment of patient with vagina dysbacteriosis
SE9900215D0 (en) 1999-01-26 1999-01-26 Pharmacia & Upjohn Ab New use
AU4905300A (en) 1999-05-25 2000-12-12 Andrew W. Bruce Oral administration of lactobacillus for the maintenance of health in women
DE19940592A1 (en) 1999-08-26 2001-03-08 Baensch Tetra Werke Portion packaging for gel feed
KR100357668B1 (en) 2000-02-19 2002-10-18 주식회사 한국야쿠르트 Lactobacillus acidophilus HY 2177, Lactobacillus casei HY 2743 having antibiotic activation for Helicobacter pylori and Lactobacillus product thereof
EP1303285A2 (en) 2000-07-17 2003-04-23 Chr. Hansen A/S Methods and formulations with probiotic microorganisms and medicaments
JP2002050872A (en) 2000-08-02 2002-02-15 Hamamatsu Photonics Kk Method and device for processing surface of multilayer printed board
CN1234373C (en) 2000-09-28 2006-01-04 信谊药厂 Medicinal preparation containing lactobacillus acidophilus and preparation process thereof
RU2203946C1 (en) 2001-09-12 2003-05-10 Хачатрян Ашот Папикович Strain of bacterium lactobacillus acidophilus nv ep 317/402-x "balans-narine" used for preparing antigastritis and antiulcerous fermented-milk product
CN100537229C (en) 2001-09-24 2009-09-09 美国杜邦泰津胶片合伙人有限公司 Multilayer polymer film for packaging ovenable food
US20050074442A1 (en) * 2002-03-13 2005-04-07 Natarajan Ranganathan Compositions and methods for augmenting kidney function
DE60323734D1 (en) 2002-03-21 2008-11-06 Bifodan As Lactobacillus strains
SE0201214D0 (en) 2002-04-23 2002-04-23 Jafar Mahdavi Multicultural fermented yogurt
GB0230042D0 (en) * 2002-12-23 2003-01-29 Britannia Pharmaceuticals Ltd Composition comprising plant extract and a sugar for use in inhibiting bacterial proliferation
US20040208863A1 (en) 2003-01-30 2004-10-21 James Versalovic Anti-inflammatory activity from lactic acid bacteria
WO2004101770A1 (en) 2003-03-13 2004-11-25 Universite De Moncton (Bureau De Soutien A L'innovation) Antioxidant producing bacterium and uses thereof
US20040185032A1 (en) 2003-03-18 2004-09-23 David Burrell Compositions and methods for treating colic
AU2004228759B2 (en) 2003-04-09 2010-04-08 Dolhay Klinika Egeszsegugyi Kft. Sexual hygienic composition
US20050017013A1 (en) 2003-07-24 2005-01-27 Alberto Peisach Container for hot fill food packaging applications
US8871266B2 (en) 2003-10-01 2014-10-28 Commonwealth Scientific & Industrial Research Organisation Probiotic storage and delivery
AU2004283626B2 (en) 2003-10-24 2010-07-15 N.V. Nutricia Synbiotic composition for infants
EP1506781B1 (en) 2003-11-03 2005-02-23 Peter-Hansen Volkmann Vaginal care composition
GB0330009D0 (en) 2003-12-24 2004-01-28 Ferrosan As Probiotic tablet formulations
GB0405406D0 (en) 2004-03-10 2004-04-21 Edko Pazarlama Tanitim Ltd Sti Anti-vaginitis compositions
EP1600061B1 (en) 2004-05-25 2010-05-12 Cognis IP Management GmbH Oral and/or topical compositions
EP1600060A1 (en) 2004-05-25 2005-11-30 Cognis IP Management GmbH Oral and/or topical compositions comprising prebiotics and fatty acid
CN101039687A (en) 2004-08-05 2007-09-19 安尼德拉尔有限公司 Folic acid producing bifidobacterium bacterial strains, formulations and use thereof
US20060039973A1 (en) 2004-08-19 2006-02-23 Mary Aldritt Effervescent composition including water soluble dietary fiber
WO2006047680A2 (en) 2004-10-27 2006-05-04 North Carolina State University Lactobacillus acidophilus nucleic acids and uses thereof
JP2006180836A (en) 2004-12-28 2006-07-13 Marudai Food Co Ltd Lactic acid bacterium controlling infection with food poisoning bacterium, fermentation product, food and medicine composition containing the same
RU2270248C1 (en) 2004-12-31 2006-02-20 Открытое акционерное общество "Лианозовский молочный комбинат" Bifidobacterium lactis 668 strain for production of fermented milk products, fermented and non-fermented foodstuffs, bioactive supplements, bacterial preparations, and cosmetics
WO2006082824A1 (en) 2005-02-03 2006-08-10 Nrl Pharma, Inc. Matrix-type enteric coated sustained release composition
US7981412B2 (en) 2005-02-15 2011-07-19 Gorbach Sherwood L Food containing a probiotic and an isolated β-glucan and methods of use thereof
CN101128129A (en) 2005-02-28 2008-02-20 纽崔西亚公司 Nutritional composition with probiotics
KR100661032B1 (en) 2005-04-19 2006-12-22 주식회사한국야쿠르트 Compositions for improving liver function, reducing blood alcohol and antioxidants
RU2303058C2 (en) 2005-06-10 2007-07-20 ООО "Витбиомед-плюс" Agent "biobalans-k" for treatment of intestine infections complicated with dysbacteriosis
EP1733872A1 (en) 2005-06-15 2006-12-20 Alcan Technology &amp; Management Ltd. Cold formable laminate
AU2006270824B2 (en) 2005-07-21 2010-09-02 Kabushiki Kaisha Yakult Honsha Novel bacterium belonging to the genus bifidobacterium and utilization of the same
WO2007020884A1 (en) 2005-08-12 2007-02-22 Meiji Dairies Corporation BIFIDOBACTERIUM OR LACTIC ACID BACTERIUM HAVING EFFECT OF PREVENTING INFECTION VIA β-DEFENSIN AND FOOD/PHARMACEUTICAL COMPOSITION CONTAINING THE SAME
ES2355064T3 (en) 2005-09-08 2011-03-22 Kabushiki Kaisha Yakult Honsha CHOLESTEROL ABSORPTION INHIBITOR.
EP1775117A1 (en) 2005-10-12 2007-04-18 Alcan Technology &amp; Management Ltd. Cold formable laminate for the making of blister base portions
PT1940243E (en) 2005-10-24 2011-10-17 Nestec Sa Dietary fiber formulation and method of administration
DE102005062731A1 (en) 2005-12-22 2007-06-28 Organobalance Gmbh New Lactobacillus strains and their use
WO2007100765A2 (en) 2006-02-28 2007-09-07 Childrens Memorial Hospital Lysozyme-modified probiotic components and uses thereof
ES2553636T3 (en) 2006-03-07 2015-12-10 Nestec S.A. Symbiotic mix
RU2318523C2 (en) 2006-03-13 2008-03-10 Лев Давидович Раснецов Antibacterial agent
EP2081607B1 (en) 2006-11-17 2015-03-18 SCA Hygiene Products AB Hygiene tissue comprising a microbe-inhibiting composition
US20080175899A1 (en) 2007-01-19 2008-07-24 Ross Mairi R Formulation for promoting sinus health in nasal cavities
US20080187628A1 (en) 2007-02-02 2008-08-07 Champion Melinda L Water-Soluble, Quick-Dissolve Flavor Tablets
ITMI20070452A1 (en) 2007-03-07 2008-09-08 Anidral Srl COMPRESSOR INCLUDING MICRO-ORGANISMS AND A COMBINATION OF EXCIPIENTS AND RELATIVE PRODUCTION PROCEDURE
EP2134835B1 (en) 2007-03-28 2014-10-15 Alimentary Health Limited Probiotic bifidobacterium strains
PL210465B1 (en) 2007-06-04 2012-01-31 Inst Biotechnologii Surowic I Szczepionek Biomed Społka Akcyjna Composition of strains type Lactobacillus and application of the composition of strains type Lactobacillus
WO2008153377A1 (en) 2007-06-15 2008-12-18 N.V. Nutricia Nutrition with non-viable bifidobacterium and non-digestible oligosaccharide
US20090175843A1 (en) * 2008-01-08 2009-07-09 Medical Nutrition Usa, Inc. Composition for prevention or treatment of urinary tract infection
US20090180999A1 (en) 2008-01-11 2009-07-16 U.S. Nutraceuticals, Llc D/B/A Valensa International Method of preventing, controlling and ameliorating urinary tract infections using cranberry derivative and d-mannose composition
US20090226548A1 (en) * 2008-01-11 2009-09-10 U.S. Nutraceuticals, Llc D/B/A Valensa International Method of preventing, controlling and ameliorating urinary tract infections using a synergistic cranberry derivative and d-mannose composition
EE05340B1 (en) 2008-05-13 2010-08-16 O� Tervisliku Piima Biotehnoloogiate Arenduskeskus Lactobacillus plantarum Tensia DSM 21380 and its use as an antimicrobial and antihypertensive probiotic in the manufacture of a medicament and for the prolongation of food shelf-life and contamination of food
DE102008023952A1 (en) 2008-05-16 2009-12-03 Alcan Technology & Management Ag Packaging cover film, container, packaging and packaging product unit
US9232813B2 (en) 2008-07-07 2016-01-12 The Iams Company Probiotic supplement, process for making, and packaging
RU2373274C1 (en) 2008-07-15 2009-11-20 Федеральное Государственное учреждение науки "Московский научно-исследовательский институт эпидемиологии и микробиологии им. Г.Н. Габричевского" Федеральной службы по надзору в сфере защиты прав потребителей и благополучия человека Bifidobacterium breve ov-12 strain, used for making bacterial preparations, bioligically active additives to food, fermented and unfermented food products, hygienic and cosmetic agents
RU2560425C2 (en) 2008-08-28 2015-08-20 Кр. Хансен А/С Stabiliser of colour in bacterial composition
US8137718B2 (en) 2008-09-19 2012-03-20 Mead Johnson Nutrition Company Probiotic infant products
US20100092240A1 (en) 2008-10-09 2010-04-15 Joseph Glasser Agricultural water retention and replenishment system
RU2388479C1 (en) 2008-11-26 2010-05-10 Государственное образовательное учреждение высшего профессионального образования "Оренбургская государственная медицинская академия Федерального агентства по здравоохранению и социальному развитию" (ГОУ ВПО ОрГМА Росздрава) Hypercholesterinemia correction method
KR101075557B1 (en) 2008-12-03 2011-10-20 씨제이제일제당 (주) Novel Lactobacillus plantarum and compositions comprising the same
EP2210505A1 (en) 2009-01-27 2010-07-28 Nestec S.A. Composition comprising caftaric acid and/or derivatives thereof
IT1400821B1 (en) 2009-03-09 2013-07-02 Probiotical Spa OIL SUSPENSION CONTAINING PROBIOTIC BACTERIA FOR PEDIATRIC USE
EP2248908A1 (en) 2009-05-05 2010-11-10 Eurolactis Group S.A. Probiotic microorganisms isolated from donkey milk
FI20095550A0 (en) 2009-05-19 2009-05-19 Bayer Schering Pharma Oy Vaginal delivery system
EP2457259A2 (en) * 2009-07-22 2012-05-30 Applied Materials, Inc. Monolithic module assembly using back contact solar cells and metal ribbon
BR112012001912A8 (en) 2009-07-27 2017-12-05 Nestec Sa NUTRITIONAL COMPOSITIONS COMPRISING FIBER AND PROBIOTICS
WO2011012932A1 (en) 2009-07-30 2011-02-03 Compagnie Gervais Danone Use of coated sterol or stanol particles for the preparation of food compositions having a low fat content and being essentially emulsifier-free
WO2011044934A1 (en) 2009-10-14 2011-04-21 Probiotical S.P.A Probiotic bacteria strains enabling of hydrolyzing prebiotic fibers and symbiotic compositions thereof
EP2364712B1 (en) * 2010-03-11 2013-03-06 Kloarys Investment Ltd Topical cosmetic or pharmaceutical composition comprising probiotic lactobacillus strains and use of same
JP2013531506A (en) 2010-06-28 2013-08-08 プロバイオティカル・ソシエタ・ペル・アチオニ Use of LACTOBACILLI to inhibit gas-producing coliforms isolated from infants suffering from colic
WO2012123770A1 (en) 2011-03-17 2012-09-20 Probiotical S.P.A. Probiotic bacteria having antioxidant activity and use thereof
ITMI20110679A1 (en) 2011-04-20 2012-10-21 Giovanni Mogna COMPOSITION INCLUDING PROBIOTIC BACTERES ABLE TO RESTORE THE BARRIER EFFECT OF THE STOMACH THAT IS LOST DURING THE PHARMACOLOGICAL TREATMENT OF GASTRICITY.
ITMI20110793A1 (en) 2011-05-09 2012-11-10 Probiotical Spa STRAINS OF PROBIOTIC BACTERIA AND SYNBIOTIC COMPOSITION CONTAINING THEMSELVES INTENDED FOR THE BABY FOOD.
ITMI20110792A1 (en) 2011-05-09 2012-11-10 Probiotical Spa STRAINS OF BACTERIA BELONGING TO THE BIFIDOBACTERIUM TYPE FOR USE IN THE TREATMENT OF HYPERCOLESTEROLEMIA.
ITMI20111718A1 (en) 2011-09-23 2013-03-24 Probiotical Spa A WATERPROOF MOISTURE AND OXYGEN MATERIAL FOR PACKAGING DIETARY, COSMETIC AND MEDICINAL PRODUCTS.
WO2013136891A1 (en) 2012-03-12 2013-09-19 オリンパス株式会社 Spectroscopic device, spectroscopic lens and spectroscopic container
JP5665141B2 (en) * 2012-09-12 2015-02-04 株式会社明治 Method for producing tromomi yogurt
ITMI20130793A1 (en) 2013-05-14 2014-11-15 Probiotical Spa COMPOSITION INCLUDING LACTIC BACTERIA FOR USE IN THE PREVENTIVE AND / OR CURATIVE TREATMENT OF THE RECURRENT CYCLES.
ITMI20130794A1 (en) 2013-05-14 2014-11-15 Probiotical Spa COMPOSITION INCLUDING LACTIC BACTERIA FOR USE IN THE PREVENTIVE AND CURATIVE TREATMENT OF BACTERIAL VAGINOSIS.

Patent Citations (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000072855A2 (en) * 1999-05-28 2000-12-07 Vsl Pharma Limited Dietary or pharmaceutical composition for use for the prevention or treatment of hyperoxaluria
EP2269465A1 (en) * 2006-05-03 2011-01-05 Probiotical S.p.a. Compositions comprising Bifidobacterium adolescentis
WO2008038075A2 (en) * 2006-09-27 2008-04-03 Mofin S.R.L. Microbial liquid cultures having high stability and fermentative activity
US20100092440A1 (en) * 2006-11-28 2010-04-15 Probiotical S.P.A. composition for the administration of biologically active principles in gynaecologic and rectal field and uses thereof
EP2338976A1 (en) * 2008-09-30 2011-06-29 Meiji Dairies Corporation Lactic acid bacterium having high oxalic acid decomposition ability
WO2010099824A1 (en) * 2009-03-05 2010-09-10 Probiotical S.P.A. Bacteria strains having a high anti-inflammatory activity
WO2010136891A1 (en) * 2009-05-27 2010-12-02 Probiotical S.P.A. Bacteriocin-producing lactobacillus pentosus and the use thereof in food and pharmaceutical compositions
EP2626076A1 (en) * 2010-03-08 2013-08-14 Probiotical S.p.a. Composition comprising probiotic bacteria for the treatment of pathologies associated with alterations of the immune system
WO2012101500A1 (en) * 2011-01-28 2012-08-02 Probiotical S.P.A. Effervescent composition in solid form for use in vaginal applications for the treatment of vaginal infections
WO2013050831A1 (en) * 2011-05-09 2013-04-11 Probiotical S.P.A. Bacterial strains capable of metabolizing oxalates
WO2013034975A1 (en) * 2011-09-09 2013-03-14 Probiotical S.P.A. Strains of lactic acid bacteria and/or bifidobacteria inhibiting/reducing the growth of different biotypes of e. coli and different biotypes of clostridia
WO2013034974A1 (en) * 2011-09-09 2013-03-14 Giovanni Mogna Composition comprising n-acetylcysteine and/or microencapsulated gastroprotected lysozyme in association with probiotic bacteria capable of restoring the stomach's own barrier effect which is lost during the pharmacological treatment of gastric hyperacidity

Non-Patent Citations (6)

* Cited by examiner, † Cited by third party
Title
FRANCO VICARIOTTO ET AL: "65: EFFECTIVENESS OF AN ASSOCIATION OF A CRANBERRY DRIED EXTRACT, D-MANNOSE AND THE THREE MICROORGANISMS L. PLANTARUM LP01, L. PARACASEI LPC09 AND S. THERMOPHILUS ST10 IN WOMEN AFFECTED BY CYSTITIS: A PILOT STUDY", 7TH PROBIOTICS & PREBIOTICS NEW FOODS, 30 July 2013 (2013-07-30), pages 1 - 52, XP055129768 *
HOESL C E ET AL: "The Probiotic Approach: An Alternative Treatment Option in Urology", EUROPEAN UROLOGY, ELSEVIER BV, NL, vol. 47, no. 3, 1 March 2005 (2005-03-01), pages 288 - 296, XP027606331, ISSN: 0302-2838, [retrieved on 20050301] *
ISMAIL AL-WAHSH ET AL: "Acute probiotic ingestion reduces gastrointestinal oxalate absorption in healthy subjects", UROLOGICAL RESEARCH ; A JOURNAL OF CLINICAL AND LABORATORY INVESTIGATION IN UROLITHIASIS AND RELATED AREAS, SPRINGER, BERLIN, DE, vol. 40, no. 3, 28 August 2011 (2011-08-28), pages 191 - 196, XP035058023, ISSN: 1434-0879, DOI: 10.1007/S00240-011-0421-7 *
MOGNA LUCA ET AL: "Assessment of the in vitro inhibitory activity of specific probiotic bacteria against different Escherichia coli strains", JOURNAL OF CLINICAL GASTROENTEROLOGY UNITED STATES, USA, vol. 46, no. Suppl, 1 October 2012 (2012-10-01), pages S29 - S32, XP009167929, ISSN: 1539-2031, DOI: 10.1097/MCG.0B013E31826852B7 *
SAGGIORO ALFREDO: "Probiotics in the treatment of irritable bowel syndrome.", JOURNAL OF CLINICAL GASTROENTEROLOGY JUL 2004, vol. 38, no. 6 Suppl, July 2004 (2004-07-01), pages S104 - S106, XP009172163, ISSN: 0192-0790 *
VIOLETA CASTRO-LEYVA ET AL: "Preserved Ex Vivo Inflammatory Status in Decidual Cells from Women with Preterm Labor and Subclinical Intrauterine Infection", PLOS ONE, vol. 7, no. 8, 22 August 2012 (2012-08-22), pages e43605, XP055077158, DOI: 10.1371/journal.pone.0043605 *

Cited By (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10982184B2 (en) 2011-05-09 2021-04-20 Probiotical S.P.A. Bacterial strains capable of metabolizing oxalates
US11110135B2 (en) 2011-05-09 2021-09-07 Probiotical S.P.A. Bacterial strains belonging to the genus Bifidobacterium for use in the treatment of hypercholesterolaemia
US11446340B2 (en) 2011-05-09 2022-09-20 Probiotical S.P.A. Probiotic bacterial strains and symbiotic composition containing the same intended for infant food
US11110136B2 (en) 2013-05-14 2021-09-07 Probiotical S.P.A. Composition comprising lactic acid bacteria for use in the preventive and/or curative treatment of recurrent cystitis
US10293008B2 (en) 2014-08-29 2019-05-21 Sami Labs Limited Process for enhancing the viable counts of lactic acid bacteria and useful compositions thereof
CN104435078A (en) * 2014-12-16 2015-03-25 汤臣倍健股份有限公司 Composition as well as application and preparation thereof
IT201900016850A1 (en) * 2019-09-20 2021-03-20 Sofar Spa Compositions based on bacterial strains and berry extracts and their use as anti-inflammatories
IT201900016865A1 (en) * 2019-09-20 2021-03-20 Sofar Spa Compositions based on bacterial strains and their use as anti-inflammatories
WO2021053642A1 (en) * 2019-09-20 2021-03-25 Sofar S.P.A. Compositions based on bacterial strains and their use as anti-inflammatories
WO2021053641A3 (en) * 2019-09-20 2021-05-20 Sofar S.P.A. Compositions based on bacterial strains and berry extracts and their use as anti-inflammatories
IT201900021483A1 (en) * 2019-11-18 2021-05-18 S I I T S R L Servizio Int Imballaggi Termosaldanti Compositions comprising xyloglucan and D-mannose and their use for the treatment of genitourinary tract disorders

Also Published As

Publication number Publication date
CN105377277A (en) 2016-03-02
RU2015148750A3 (en) 2018-03-05
US11110136B2 (en) 2021-09-07
PL2996700T3 (en) 2021-03-08
US20210308197A1 (en) 2021-10-07
KR20160008236A (en) 2016-01-21
BR112015027536A8 (en) 2018-01-23
ES2831900T3 (en) 2021-06-09
RU2015148750A (en) 2017-06-19
CA2912013A1 (en) 2014-11-20
EP2996700B1 (en) 2020-10-28
JP2016518441A (en) 2016-06-23
JP6600623B2 (en) 2019-10-30
EP2996700A1 (en) 2016-03-23
ITMI20130793A1 (en) 2014-11-15
DK2996700T3 (en) 2020-11-23
BR112015027536A2 (en) 2017-09-12
WO2014184639A9 (en) 2015-01-15
US20160106787A1 (en) 2016-04-21
KR102261724B1 (en) 2021-06-07

Similar Documents

Publication Publication Date Title
US20210308197A1 (en) Composition comprising lactic acid bacteria for use in the preventive and/or curative treatment of recurrent cystitis
JP5777640B2 (en) Probiotic compositions for use in the treatment of intestinal inflammation
Li et al. Efficacy and safety of probiotics in the treatment of C andida‐associated stomatitis
JP6130379B2 (en) Composition comprising N-acetylcysteine and / or microencapsulated gastroprotective lysozyme in combination with probiotic bacteria capable of repairing the gastric barrier effect lost during gastric acidity drug treatment
Reid et al. Cranberry juice consumption may reduce biofilms on uroepithelial cells: pilot study in spinal cord injured patients
EP2996701B1 (en) Composition comprising lactic acid bacteria for use in the preventive and/or curative treatment of bacterial vaginosis
EP2712318B1 (en) Composition comprising probiotic bacteria capable of restoring the barrier effect of the stomach which is lost during pharmalogical treatment of gastric hyperacidity
Del Popolo et al. Recurrent bacterial symptomatic cystitis: A pilot study on a new natural option for treatment
WO2014184644A1 (en) Composition comprising lactic acid bacteria and/or bifidobacteria for use in the preventive and/or curative treatment of bacterial infections and/or inflammations of the urinary tract and/or prostate which are the cause of prostatitis and prostatic hypertrophy
US9889166B2 (en) Treating low production of mucus in the gastrointestinal tract with S. thermophilus
CN110234331A (en) MRSA infects protective agent
WO2009008569A1 (en) Production methods of green tea extracts for preventing adhesion of pathogenic bacteria to human cell
Devkar et al. Probiotics and prebiotics in periodontal disease-revisited
Dhawan et al. Role of probiotics on oral health–A randomized, double blind, placebo-controlled microbiological study
Aji et al. The Probiotic Role of Lactic Acid Bacteria (LAB) in Helicobacter Pylori Gastritis
Verrucci et al. Use of probiotics in medical devices applied to some common pathologies.
WO2011000124A1 (en) Pharmaceutical composition including viable probiotic strains of lactobacillus spp. used for the prevention and recovery of individuals with urinary tract infections and immunocompromised individuals
ITMI20121173A1 (en) DIETARY AND PHARMACEUTICAL COMPOSITIONS INCLUDING LACTOBACILLUS AND BIFIDOBACTERIUM STRIPS ABLE TO DEGRATE OXALATES AND TO INDUCE AN ANTI-INFLAMMATORY IMMUNITY RESPONSE
S Pavlakis Prevention of Recurrent Cystitis in Pre-Menopausal Women: From Mechanisms to Therapy
Pevec Role of synbiotics in reducing postoperative infections in patients with hip fracture: pilot study
BR102013026249B1 (en) probiotic chewing gum for prevention of cavities and other oral infections and manufacturing process

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 14732360

Country of ref document: EP

Kind code of ref document: A1

ENP Entry into the national phase

Ref document number: 2912013

Country of ref document: CA

ENP Entry into the national phase

Ref document number: 2016513453

Country of ref document: JP

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 14891306

Country of ref document: US

NENP Non-entry into the national phase

Ref country code: DE

REG Reference to national code

Ref country code: BR

Ref legal event code: B01A

Ref document number: 112015027536

Country of ref document: BR

ENP Entry into the national phase

Ref document number: 20157035288

Country of ref document: KR

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 2014732360

Country of ref document: EP

ENP Entry into the national phase

Ref document number: 2015148750

Country of ref document: RU

Kind code of ref document: A

ENP Entry into the national phase

Ref document number: 112015027536

Country of ref document: BR

Kind code of ref document: A2

Effective date: 20151029